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ABSTRACT 
Poly(NIPAAm-co-AAm)-gold nanoshell composites for optically-triggered 
cancer therapeutic delivery 
by 
Laura Elizabeth Strong 
 
Cancer is currently the second leading cause of death in the United States. Although 
many treatment options exist, some of the most common, including radiotherapy and 
chemotherapy, are restricted by dose-limiting toxicities. For example, for 2-6% of patients 
receiving a regimen of the chemotherapeutic doxorubicin, irreversible cardiotoxicity will 
occur1, causing these patients to immediately cease treatment. In addition, the largest hurdle 
for translating novel biological therapies such as siRNA into the clinic is lack of an efficient 
delivery mechanism to get the therapeutic into malignant cells2. Both of these situations 
would benefit from a minimally invasive controlled release system that only delivers a 
therapeutic to the site of malignant tissue. This thesis presents work towards the creation of 
such a delivery platform using two novel material components: a thermally responsive 
poly[N-isopropylacrylamide-co-acrylamide] (NIPAAm-co-AAm) hydrogel and gold-silica 
nanoshells. Thermally responsive hydrogels go through a physical property transition at their 
lower critical solution temperature (LCST). When transitioning from below to above the 
LCST, the hydrogel material expels large amounts of water and absorbed molecules. This 
phase change can be optically triggered by embedded gold-silica nanoshells, which rapidly 
transfer near-infrared (NIR) light energy into heat energy due to the surface plasmon 
resonance phenomena. When this material is loaded with absorbed drug molecules, drug 
release can be externally triggered by exposure to an NIR laser. 
Initial characterization of this material was done using bulk hydrogel-nanoshell 
composites. Poly(NIPAAm-co-AAm)-nanoshell composites were synthesized via free radical 
polymerization. The LCST of the poly(NIPAAm-co-AAm) hydrogels was determined to be 
from 39-45 oC, or slightly above physiologic temperature. The material was swollen in a drug 
solution of either doxorubicin (a common chemotherapeutic) or a 21bp dsDNA olgio (a 
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model molecule for siRNA). Composites were then exposed to an 808 nm laser at 8 W/cm2, 
which was found to trigger release of the therapeutics from the composite material.  
Further work has been done in translating this composite material to nano-scale sized 
particles, such that it could be injected intravenously and passively accumulate in tumor 
tissue. Sub-micron composite particles were synthesized using dissolvable gelatin templates 
with 500 nm wells. Analysis by transmission electron microscopy (TEM) shows that these 
particles consist of gold nanoshells surrounded by a hydrogel coating. Analysis by dynamic 
light scattering (DLS) shows that these particles display the same thermal properties as seen 
in the bulk material, collapsing in response to increased temperatures and NIR light exposure. 
Ultimately, the work in this thesis advances the development of a minimally-invasive, 
optically-triggered drug delivery platform.  
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1 INTRODUCTION: CANCER BIOLOGY, CLINICAL MANAGEMENT, 
AND CONTROLLED DRUG DELIVERY 
1.1 MOTIVATION !
In 2010, cancer was the second leading cause of death in the United States following 
heart diseases, accounting for approximately 1500 deaths/day3. In addition, over the past 15+ 
years, the death rate due to heart disease rate has decreased 40%, while the cancer death rate 
has only been reduced by 18% as seen in Figure 1.13. Furthermore, the cost of cancer was 
estimated to be $263.8 billion annually3.  These statistics indicate that advances in cancer 
treatments are still needed in order to better manage this disease. The work in this thesis aims 
to improve cancer treatment by utilizing a novel platform to better control the delivery of 
cancer therapeutics. 
!
Figure 1.1. US mortality rates for several diseases in 1991 and 2007. Information age adjusted to 
2000 US standard population. From Ref 3. 
1.2 CANCER HALLMARKS !
Cancer is widely recognized to be a disease involving dynamic changes in the 
genome. It occurs in a wide variety of cell types and tissues but is universally characterized 
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by cell changes that allow for unregulated cell cycle progression and growth. Tumorigenesis 
is a multistep process in which each step reflects genetic alterations that drive a progressive 
transformation of normal cells into highly malignant derivatives4. In a 2000 review, Hanahan 
and Weinburg assert that this transformation into a malignant state manifests in six essential 
alterations in cell physiology: (1) self-sufficiency in growth signals, (2) insensitivity to 
growth-inhibitory (anti-growth) signals, (3) limitless replicative potential, (4) evasion of 
programmed cell death (apoptosis), (5) sustained angiogenesis, and (6) tissue invasion and 
metastasis4. The authors note that these capabilities are shared in common by most, if not all 
types of human tumors.  
Over the past 10 years, progress in cancer research has led to new observations that 
serve to both clarify and modify the original six hallmarks. In response, Hanahan and 
Weinburg wrote another review in 2011, in which four new concepts were discussed5. Two 
of these new concepts, (1) genome instability and mutation and (2) tumor-promoting 
inflammation, are thought be critical to the scope and conceptualization of the original six 
hallmarks. In addition, two new, unique hallmarks were recognized: (1) reprogramming of 
energy metabolism and (2) evading immune destruction.  
1.3 CANCER THERAPY !
 Conventional cancer treatments include surgery, radiation therapy, and chemotherapy. 
These treatments may be used alone but are often used in combination. The goal of each 
treatment option is to kill as much malignant tissue as possible while minimizing harm to 
surrounding healthy tissues.  
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 Surgical therapy involves the physical removal (resection) of the tumor mass. This is 
the most effective treatment for localized disease. It is common for adjacent, healthy tissue to 
be resected during surgery to help pathologists determine if the tumor is invading 
surrounding tissue and decrease the risk of recurrence or metastasis. However, surgery is not 
applicable for tumors in inaccessible anatomic locations or in cases with extensive 
intermingling of tumor and critical normal tissues6.  
 In radiation therapy, tumor cells are exposed to ionizing radiation resulting in cell 
death when the cell tries to divide. Therefore, this therapy is most toxic to highly 
proliferative cells, including cancer cells. However, both malignant cells and healthy tissue 
use the same mechanism for cell division, and thus, radiation therapy also kills rapidly 
dividing normal cells within renewing tissues such as hair follicles, oral-gastrointestinal 
epithelium, and hematopoietic tissue. These off-site toxicities, along with other chronic 
toxicities, ultimately determine the maximum dose of radiation a patient may receive in his 
or her lifetime6.  
 Chemotherapy is defined as the use of drugs to treat or control cancer. These drugs 
are often given systemically and aim to target highly proliferative cells. These types of drugs 
include alkylating agents, antimetabolites, natural or semisynthetic products, and hormones 
or hormone inhibitors7. The drugs are generally cell cycle phase-specific, as demonstrated in 
Figure 1.2, and thereby target highly proliferative cells to a greater degree than more dormant 
tissues8.  
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Figure 1.2. Cell cycle schematic and respective sensitivity to chemotherapeutic agents. Most 
agents are active in the S and M phases of the cell cycle and thereby target more proliferative tissues 
to a higher degree than more dormant tissues Adapted from Seiwert et al. 20078. 
Like radiation therapy, off-site toxicities of chemotherapeutics are significant in tissues that 
are normally in a highly proliferative state, such as the bone marrow, gastrointestinal tract, 
and hair follicles7. This leads to the side effects that most people associate with 
chemotherapy regimens: immunosuppression, nausea, and alopecia. However, many 
chemotherapeutics also have less common toxic reactions, including pulmonary fibrosis 
(seen with bleomycin, buslfan, and mitocycin C) and cardiotoxicity (seen with doxorubicin, 
daunomycin, mitoxantrone, and idarubicin)7. These severe toxicities often lead to restrictions 
in the total doses of these drugs that may be administered7. If a patient experiences one of 
these toxicities, treatment often has to be ceased immediately, even if the drug is effective 
against the malignant cells. These drugs would benefit from administration in a manner that 
minimizes drug exposure to healthy tissues. A more detailed explanation of controlled drug 
delivery can be found in Section 1.3.2. 
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1.3.1 Emerging Therapy: siRNA 
 
 In recent years, advancing technologies in molecular biology have demonstrated that 
small segments of RNA can be used as a genetics-based cancer therapy. In RNA interference, 
double stranded RNA (dsRNA) hinders the expression of a target gene as a result of 
sequence homology2. This process occurs naturally in mammalian cells, where the enzyme 
Dicer initiates RNA silencing by breaking down long dsRNA molecules into small 
interfering RNA (siRNA) segments of around 21-23 nucleotides2. The siRNA molecules go 
on to bind to complementary sequences in cytosolic mRNA transcripts, thereby preventing 
protein translation of the binding targets. The overall process of RNA interference is 
summarized in Figure 1.39.  
 
Figure 1.3 Cellular mechanisms of RNA interference. First, dsRNA is cleaved by Dicer into 
siRNA. These siRNAs are then incorporated into the RNA-induced silencing complex (RISC), where 
the strands are separated. The RISC complex containing the antisense strand seeks out to bind to 
complementary mRNA sequences. These mRNA sequences are than cleaved by the enzyme 
Argonaute, thereby causing mRNA degradation and preventing protein translation. From Bumcrot et 
al. 20069. 
shown in Figure 2. Stability against nuclease degradation has been 
achieved by introducing a phosphorothioate (P=S) backbone linkage at 
the 3′ end for exonuclease resistance and 2′ modifications (2′-OMe, 2′-F 
and related) for endonuclease resistance8–10. An siRNA motif, consisting 
entirely of 2′-O-methyl and 2′-fluoro nucleotides, has enhanced plasma 
stability and increased in vitro potency. At one site, this motif shows 
>500-fold improvement in potency over the unmodified siRNA11. Using 
phosphatase and tensin homolog (PTEN) as a target, the effect of 2′ 
sugar modifications such as 2′-fluoro-2′-deoxynucleoside (2′-F), 2′-O-
methyl (2′-O-Me) and 2′-O-(2-methoxyethyl) (2′-O-MOE) in the guide 
and nonguide strands was evaluated in HeLa cells. The activity depends 
on the position of the modification in the guide-strand sequence. The 
siRNAs with modified residues at the 5′ end of the guide strand seem 
to be less active than those modified at the 3′ end. The 2′-F sugar is 
generally well tolerated on the guide strand, whereas the 2′-O-MOE 
modification results in loss of activity regardless of placement position 
in the construct. The incorporation of 2′-O-Me and 2′-O-MOE in the 
nonguide strand of siRNA does not have a notable effect on activity12. 
Sugar modifications such as 2′-O-Me, 2′-F and locked nucleic acid (LNA, 
with a methylene bridge connecting 2′ and 4′ carbons) seem to be able to 
reduce the immunostimulatory effects of siRNAs (see below).
Duplexes containing the 4′-thioribose modification have a stability 
600 times greater than that of natural RNA13. Crystal structure studies 
reveal that 4′-thioriboses adopt conformations very similar to the C3′-
endo pucker observed for unmodified sugars in the native duplex14. 
Stretches of 4′-thio-RNA were well tolerated in both the guide and non-
guide strands. However, optimization of both the number and the place-
ment of 4′-thioribonucleosides is necessary for maximal potency. These 
optimized siRNAs are generally equipotent with or superior to native 
siRNAs and show increased thermal and plasma stability. Furthermore, 
substantial improvements in siRNA activity and plasma stability have 
been achieved by judicious combination of 4′-thioribose with 2′-O-Me 
and 2′-O-MOE modifications15.
As mentioned, phosphorothioate (P=S) modifications are gener-
ally well tolerated on both strands and provide improved nuclease 
resistance. The 2′,5′-phosphodiester linkages seem to be tolerated in 
the nonguide but not the guide strand of the siRNA16. In the borano-
phosphate linkage, a nonbridging phosphodiester oxygen is replaced 
by an isoelectronic borane (BH3-) moiety. Boranophosphate siRNAs 
have been synthesized by enzymatic routes using T7 RNA polymerase 
and a boranophosphate ribonucleoside triphosphate in the transcrip-
tion reaction. Boranophosphate siRNAs are more active than native 
siRNAs if the center of the guide strand is not modified, and they 
may be at least ten times more nuclease resistant than unmodified 
siRNAs17,18.
siRNA duplexes containing the 2,4-difluorotoluyl ribonucleoside 
(rF) were synthesized to evaluate the effect of noncanonical nucleoside 
mimetics on RNA interference. Thermal melting analysis showed that 
the base pair between rF and adenosine is destabilizing relative to a uri-
dine-adenosine pair, although it is slightly less destabilizing than other 
mismatches. The crystal structure of a duplex containing rF-adenosine 
pairs shows local structural variations relative to a canonical RNA helix. 
As the fluorine atoms cannot act as hydrogen bond acceptors and are 
more hydrophobic than uridine, a well-ordered water structure is not 
seen around the rF residues in both grooves. Rapid amplification of 
5  complementary DNA ends (5′-RACE) analysis confirms cleavage of 
target mRNA opposite to the rF placement site19,20.
Certain terminal conjugates have been reported to improve or direct 
cellular uptake. For example, siRNAs conjugated with cholesterol 
improve in vitro and in vivo cell permeation in liver cells6. As described 
below, cholesterol and an RNA aptamer conjugation show promise in 
animal models.
Design considerations for potency and specificity
Critical design concerns in the selection of siRNA duplexes for therapeu-
tic use are potency and specificity. There are two major considerations 
mRNA
mRNA
degradation
dsRNA
Dicer Cleavage
Strand separation
Complementary pairing
Cleavage
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mRNA
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Figure 1  Cellular mechanism of RNA interference. Long double-stranded RNA (dsRNA) is cleaved, by the enzyme Dicer, into small interfering RNA (siRNA). 
These siRNAs are incorporated into the RNA-induced silencing complex (RISC), where the strands are separated. The RISC containing the guide or antisense 
strand seeks out and binds to complementary mRNA sequences. These mRNA sequences are then cleaved by Argonaute, the enzyme within the RISC 
responsible for mRNA degradation, which leads to mRNA down-modulation. A, adenosine.
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This biological mechanism can be exploited for cancer therapy by the introduction of 
synthetic siRNA targeted to a gene of choice. Elbashir et al. first showed that the 
introduction of a 21-nucleotide artificial siRNA could trigger gene silencing in!mammalian 
cells10. This proof of concept study demonstrated the downregulation of several different 
genes coding for various firefly luciferases10. Since then, siRNA has been used to 
downregulate key proteins in the progression of cancer showing great therapeutic potential. 
As a result, siRNA has been investigated for use in the treatment of cancers of the breast, 
ovary, cervix, liver, lung, prostate, and others2. Furthermore, several siRNA molecules have 
advanced to human clinical trials, as shown in Table 1.1.  
Table 1.1. siRNA Therapeutics in Clinical Trials. From Oh et al. 20092. 
 
siRNA therapy has several advantages over more traditional therapeutic strategies. First, 
siRNA interferes with translation, not with DNA transcription as seen in DNA-based gene 
therapy approaches. Therefore, this approach minimizes concerns about possible adverse 
gene alterations2. Another advantage is that siRNA can act on a wide range of protein targets, 
whereas traditional chemical drugs are limited to acting on certain classes of receptors, ion 
channels, or enzymes. Current biological therapies, including monoclonal antibodies and 
cytokines, mainly target moieties on the cell surface. siRNAs, however, can target any 
mRNA regardless of the cellular location of the translated protein2.  
with the dsRNA. The RNAi machinery, ﬁrst discovered in plants,
was later demonstrated in the roundworm Caenorhabditis elegans by
delivery of dsRNA using a microinjection technique. The introduction
of dsRNA molecules could produce the interfering activity and result
in the highly speciﬁc inhibition of complementary gene expression in
C. elegans [1].
Recent studies have provided insights into the molecular mechan-
isms of RNAi, in which dsRNA induces the silencing of homologous
mRNA. In the cytoplasm of mammalian cells, an enzyme known as
Dicer initiates RNA silencing by breakdown of long dsRNA to generate
small interfering RNA (siRNA) of about 21–23 nucleotides in length.
The resulting siRNAs are incorporated into an RNA-induced silencing
complex (RISC) and unwound into a single-stranded RNA (ssRNA),
which is followed by the degradation of sense strand ssRNA [2]. The
RISC containing ssRNA, a guide or antisense strand, looks for and binds
to complementary mRNA molecules. The main components of the
RISC complex are the Argonaute 2 protein, which is a member of the
Argonaute family of proteins, responsible for mRNA degradation and
ssRNA formation [3]. As a catalytic engine within RISC, Argonaute 2
(previously known as eIF2C2) facilitates guiding of the anti-sense
ssRNA strand to complementarymRNA sequences and degrades target
mRNAs through the PIWI domain of an Ago protein, a structural
homolog of RNase H. ATP is not essential for the target cleavage
reaction of RISC, although ATP increases the rate of endonuclease
activity. The hydrolysis reaction involved in the breakdown of the
target mRNA phosphodiester backbone requires a divalent metal ion
(Mg2+) and releases the 5'-PO4 and 3'-OH groups [4–8].
Although siRNA is naturally generated from a long dsRNA, syn-
thetic siRNA can affect RNAi. The introduction of an artiﬁcial siRNA
of 21 nucleotides triggered gene silencing in mammalian cells [9].
siRNA molecules blocked speciﬁc expression of endogenous and
heterologous genes in various mammalian cell lines [9]. Moreover,
the multiple administrations of synthetic siRNAs achieved long-term
silencing of target gene without disrupting the endogenous microRNA
pathways [10].
Such work has generated much interest in the potential of
synthetic siRNA as a key strategic molecule in biomedical research
and in the development of innovative medicines. Indeed, siRNAs have
been extensively used for the functional analysis of speciﬁc genes,
especially genes overexpressed in cancer cells, and for the develop-
ment of new therapeutics for various incurable diseases.
In this paper, we review therapeutic potentials of nonviral siRNA
delivery strategies for treatment of various cancers.
2. Therapeutic applications and challenges of siRNA usage
2.1. siRNA in clinical trials
Given their speciﬁc and potent RNAi triggering activity, siRNAs are
emerging as new generation biodrugs. Several studies have upported
the therapeutic potential of siRNA. Viral mRNA-targeted siRNA has
been shown to be effective in inhibiting different stages of the HIV
virus life cycle [11]. The hydrodynamic injection of Fas-speciﬁc siRNA
prevented liver failure in mice with chronic and severe autoimmune
hepatitis [12]. Currently, several potential siRNA candidates are under-
going clinical trials for treatment of macular degeneration, respiratory
diseases, and cancers.
The double stranded RNA-based molecule, siRNA, has a high
potential as biopharmaceutical therapeutics. As RNAi interferes with
translation, and not with DNA transcription, siRNA may not interact
with chromosomal DNA. This lack of DNA interaction greatly reduces
concerns about possible adverse gene alteration that might result
from DNA-based gene therapy. The interaction of siRNA with mRNA,
not protein, alsomakes it possible to reduce the production of harmful
proteins before synthesis.
Anothermerit of siRNA as a therapeutic drug is that awide range of
target proteins can be utilized for gene silencing to treat diseases [13].
Conventional targets of traditional chemical drugs have been limited
to certain classes of receptors, ion channels, and enzymes. Current
biological drugs such as monoclonal antibodies or cytokines target
moieties mainly present on the cell surface or in the blood. In contrast,
an siRNA-based drug can target any mRNAs of interest, regardless of
their cellular location of the translated proteins. Moreover, siRNA is
considered to be potent, as only a few siRNA molecules per cell are
required to produce effective gene silencing [14,15].
The identiﬁcation of appropriate drug candidates is more straight-
forward using siRNA than traditional pharmaceuticals, so the devel-
opment of siRNA-based therapeutics has progressed rapidly. Some
lead siRNA c ndidates entered clinical trials only 10 years after the
discovery of the RNAi mechanism [16]. Most siRNAs in clinical trials
are administered by local delivery such as the intravitreal or intranasal
routes (Table 1). The ﬁrst clinical trials of siRNA for treatment of wet
neovascular age-related macular degeneration (AMD), using siRNA
targeting the vascular endothelial growth factor (VEGF) signaling
pathway, have commenced. Recently, phase I and II trials to assess the
safety, tolerability, and efﬁcacy of the siRNA Cand5 (bevasiranib; Opko
Health Inc.), which targets VEGF, in AMD patients have been
completed and a phase III trial has been initiated. Sirna Therapeutics'
Sirna-027 (termed AGN211745), a chemically modiﬁed siRNA target-
ing VEGF receptor 1, has entered a phase II trial and seems to provide
clinically signiﬁcant improvement in visual acuity, with no serious
adverse events or dose-limiting toxicities, in a relevant subset of
patients. Another AMD siRNA candidate, RTP-801i, blocks REDD-1
gene expression and has been investigated in a phase I clinical trial.
The ﬁrst siRNA against respiratory viral infection is the intranasal ALN-
RSV01 of Alnylam Pharmaceuticals, which targets respiratory syncy-
tial virus (RSV). ALN-RSV01 is currently being investigated in a second
phase II trial in naturally infected adult patients [17]. For treatment of
chronic hepatitis B virus (HBV) infection, ucleonics has begun a
phase 1 human safety study of NUC B1000. NUC B1000 is an siRNA-
based product designed to reduce the malignant effects of hepatitis
and is systemically administered using a cationic lipid formulation.
Calando Pharmaceuticals' siRNA therapeutic CALAA-01 is a
cyclodextrin-based polymeric nanoparticle containing an siRNA that
Table 1
siRNA therapeutics undergoing clinical trials.
Companies Product Target gene Target disease Route of administration Status
Opko Health Bevasiranib (Cand 5) VEGF AMD Intravitreal Phase III
DME Phase II
Allergan AGN211745 (Sirna-027) VEGF receptor AMD Intravitreal Phase II
Alnylam Pharmaceuticals ALN-RSV01 RSV RSV infection Intranasal Phase II
Quark Pharmaceuticals RTP801i-14 RTP801 AMD Intravitreal Phase I
AKIi-5 p53 ARF Intravenous Phase I
Calando Pharmaceuticals CALAA-01 M2 subunit of ribonucleotide reductase Solid tumor Intravenous Phase I
Nucleonics NUC B1000 HBV `HBV infection Intravenous Phase I
TransDerm TD101 Single nucleotide mutation in the keratin 6a PC Intradermal Phase I
VEGF: Vascular endothelial growth factor, DME: Diabetic macular edema, RSV: respiratory syncytial virus, AMD: age-relatedmacular degeneration, HBV: Hepatitis B virus, ARF: Acute
renal failure, PC: Pachyonychia congenital.
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 A major challenge in the translation of siRNA therapy to the clinic is the efficient 
delivery of the molecule into target cells2. RNA is anionic and hydrophilic and therefore 
cannot enter cells by passive diffusion. In addition, RNA molecules injected intravenously 
are quickly degraded by serum enzymes and cleared rapidly through the kidneys9. 
Furthermore, these molecules have limited penetration across capillary endothelium and 
inefficient uptake by parenchymal cells9. Development of an in vivo delivery system for 
siRNA is paramount for an efficient therapeutic effect to take place2. 
1.3.2 Controlled Delivery Methods !
 Therapeutic efficacy of both chemotherapeutics and biological therapeutics such as 
siRNA would benefit from administration in a controlled delivery manner. Controlled 
delivery systems can influence the performance of a therapeutic agent by manipulation of its 
effective concentration, location, and duration11. Drug delivery via controlled release offers 
several advantages to improve cancer therapy including (1) localized delivery of the drug to a 
particular tissue, thereby lowering the systemic drug level, (2) preservation of drugs that are 
rapidly broken down by the body, (3) reduced need for follow-up care, (4) increased comfort, 
and (5) improved compliance12.  
The field of controlled drug release has grown dramatically from the 1940s when 
sustained release products aiming to reduce the frequency of dosing first came on the market. 
Today a wide range of self-regulating systems deliver a variety of molecules including genes, 
proteins, and other therapeutics11.  In fact, in a review dating back to 1981, Langer and 
Peppas noted that while synthesis and discovery of new potent drugs is important, critical 
attention should also be given to the manner in which these drugs are delivered13. Current 
! 8 
research in cancer medicine also focuses on the synthesis and discovery of new and effective 
drugs. In fact, Hanahan and Weinburg described several drugs that aim to interfere with each 
of the acquired hallmarks of cancer in their recent review (Figure 1.4)5.  
!
Figure 1.4. Therapeutic targeting of the ten hallmarks of cancer. Drugs that interfere with each 
acquired capability of cancer cells listed are either in clinical trials or approved for clinical use in 
certain forms of cancer. From Hanahan and Weinburg 20115. 
In addition to this focus on novel drugs, new methods of delivery should also be 
investigated. The chemotherapeutic off-site toxicities mentioned previously, which tend to be 
responsible for failed or aborted chemotherapy regimens, could be minimized by use of a 
controlled delivery system. This system would provide burst drug delivery only to malignant 
tissue, effectively minimizing drug exposure to non-malignant tissues.  
therapie . For example, the deployment of apoptosis-inducing
drugs may induce cancer cells to hyperactivate mitogenic
signaling, enabling them to compensate for the initial attrition
triggered by such treatments. Such considerations suggest
that drug development and the design of treatment protocols
will benefit from incorporating the concepts of functionally
discrete hallmark capabilities and of the multiple biochemical
pathways involved in supporting each of them. Thus, in partic-
ular, we can envisage that selective cotargeting of multiple
core and emerging hallmark capabilities and enabling character-
istics (Figure 6) in mechanism-guided combinations will result in
more effective and durable therapies for human cancer.
CONCLUSION AND FUTURE VISION
We have sought here to revisit, refine, and extend the concept of
cancer hallmarks, which has provided a useful conceptual
framework for understanding the complex biology of cancer.
The six acquired capabilities—the hallmarks of cancer—have
stood the test of time as being integral components of most
forms of cancer. Further refinement of these organizing princi-
ples will surely come in the foreseeable future, continuing the
remarkable conceptual progress of the last decade.
Looking ahead, we envision significant advances during the
coming decade in our understanding of invasion andmetastasis.
Similarly, the role of aerobic glycolysis in malignant growth will
be elucidated, including a resolution of whether this metabolic
reprogramming is a discrete capability separable from the core
hallmark of chronically sustained proliferation. We remain
perplexed as to whether immune surveillance is a barrier that
virtually all tumors must circumvent, or only an idiosyncrasy of
an especially immunogenic subset of them; this issue too will
be resolved in one way or another.
Yet other areas are currently in rapid flux. In recent years, elab-
orate molecular mechanisms controlling transcription through
chromatin modifications have been uncovered, and there are
Figure 6. Therapeutic Targeting of the Hallmarks of Cancer
Drugs that interfere with each of the acquired capabilities necessary for tumor growth and progression have been developed and are in clinical trials or in some
cases approved for clinical use in treating certain forms of human cancer. Additionally, the investigational drugs are being developed to target each of the
enabling characteristics and emerging hallmarks depicted in Figure 3, which also hold promise as cancer therapeutics. The drugs listed are but illustrative
examples; there is a deep pipeline of candidate drugs with different molecular targets and modes of action in development for most of these hallmarks.
668 Cell 144, March 4, 2011 ª2011 Elsevier Inc.
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There are some controlled delivery systems on the market today, most notably Doxil®, 
which is a poly(ethylene glycol) [PEGylated] liposome containing the chemotherapeutic 
doxorubicin14. This formulation increases the serum half-life of the drug, thereby ensuring a 
higher percentage of the administered dose reaches the tumor site14. However, Doxil® is 
given systemically and some drug will diffuse out of the liposome over time, leading to off-
site toxicity.  
Another commercially available delivery system is bis-chloronitrosourea (BCNU) 
wafers (Gliadel®) for the management of brain malignancies. This therapy consists of 
polifeprosan 20 wafers loaded with the chemotherapeutic Carmustine. These wafers are 
implanted directly into the brain during surgical tumor resection, and slowly release drug 
over time to prevent recurrence15. However, surgical access is necessary for implantation 
making this strategy inapplicable for some cancer sites. A non-invasive drug delivery system 
that allows drug release to occur only at the tumor site would be advantageous over existing 
drug delivery systems.  
1.4 CONCLUSIONS  !
The systems discussed in this section are not without their limitations. A non-invasive 
platform, which can be externally triggered to release a therapeutic only at the site of 
malignant tissue, would be an improvement in cancer management. This thesis investigates 
such a system. This platform will be comprised of two novel material components: gold-
silica nanoshells and a thermally responsive polymer coating. The polymer coating would 
contain drug, allowing the drug-filled particles to circulate throughout the body without the 
drug acting on tissue. At the appropriate delivery site, the optical properties of the gold-silica 
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nanoshells would be exploited to increase the particle temperature and trigger drug release. A 
background on these two material components follows in Chapter 2.   
!
!!!!!!!!!!!!!!!!!!!!!!
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2 MATERIAL COMPONENTS1 
 
2.1 INTRODUCTION !
The work in this thesis involves two unique materials: a gold-based nanoparticle and a 
thermally responsive hydrogel. This chapter provides background information on these two 
materials as well as examines previous studies of these materials in relation to cancer 
management and drug delivery. The chapter concludes with combinations of these two 
materials as well as remarks regarding current limitations. 
2.2 GOLD NANOPARTICLES !
Nanoparticles have been highly investigated for use in biological and medical 
applications due to their unique size and optical properties. The four main gold nanoparticle 
types that will be further discussed are solid gold nanoparticles (AuNPs), gold-gold sulfide 
(Au-Au2S) nanoparticles, gold-silica (SiO2-Au) nanoshells, and gold nanorods. All of these 
particles are of importance in biomedical applications because of their ability to induce 
localized heating upon exposure to light.  Additional properties of these particles are 
summarized in Table 2.1.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Portions of this chapter have been adapted from the publication: L.E. Strong and J.L. West. 
“Thermally Responsive Polymer-Nanoparticle Composites for Biomedical Applications.” Wiley 
interdisciplinary reviews. Nanomedicine and nanobiotechnology. 2011;3(3):307-17. !
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Table 2.1. Nanoparticle Properties16–20. 
 
2.2.1 Optical Properties !
When a gold-based nanoparticle is irradiated with light at the wavelength of its 
surface plasmon resonance, this light is rapidly transferred into thermal energy, causing a 
localized temperature increase16–18. Au-Au2S nanoparticles, Silica-Au nanoshells, and Au 
nanorods can all be tuned to have a surface plasmon resonance in the near infrared (NIR) 
range17–20. The NIR range (700-900 nm) is above the absorption of biological molecules such 
as hemoglobin (<650 nm) and below the range absorbed by water (>900 nm)21. Thus, NIR 
light is of particular interest for biological applications, as these wavelengths penetrate 
biological tissue with relatively little attenuation or tissue damage, as illustrated in Figure 
2.121.  
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Figure 2.1. Tissue permeability of NIR light. Near-infrared light (650-900 nm) is of particular 
interest in biological applications as it is minimally absorbed by biological chromophores and water. 
From Weissleder 200121. !
2.2.2 Types of Gold Nanoparticles  !
Gold nanoparticles (AuNPs, also called gold colloids) are one of the most stable and 
highly investigated metal nanoparticle16.  These particles, thought of as “soluble gold” in 
antiquity, were used for aesthetic and curative purposes as early as the 4th and 5th centuries 
B.C16. Several synthesis techniques exist, the most common being citrate reduction of 
chloroauric acid (HAuCl4) in water22. These particles (with diameters ranging from 2-100 
nm) have maximum absorption around 520-575 nm, depending on the diameter of the 
particles, with the smaller particles maximally absorbing at a lower wavelength16.  
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2.2.2.1 Gold-gold sulfide nanoparticles !
Gold-gold sulfide (Au-Au2S) nanoparticles were first developed by Zhou et al.23. Due 
to their optical properties, these particles were originally thought to consist of a dielectric 
gold-silica core surrounded by a thin gold shell18.  Controversy still remains over the exact 
structure of these particles; however the core/shell model fits the optical data and surface 
conjugation studies suggest a continuous gold coating24. These nanoparticles are synthesized 
by mixing HAuCl4 and sodium sulfide (Na2S)23.  The ratios of these two materials can be 
adjusted to alter the surface plasmon resonance of the particles from 600 nm to greater than 
1000 nm25. Much research has been done on Au-Au2S nanoparticles that are NIR absorbing; 
these particles generally have a 35-55 nm diameter and surface plasmon resonance near 800-
900 nm18,26–30.   
2.2.2.2 Gold-silica nanoshells !
Gold-silica nanoshells were developed by Oldenburg et al. through molecular self-
assembly and colloid reduction chemistry31.  These particles consist of a dielectric silica core 
surrounded by a solid gold shell, and adjustments of these two parameters provide control 
over the optical properties of the particles, as seen in Figure 2.219. The peak extinction 
coefficients of these particles can range from visible to near-infrared and even infrared 
ranges19. Most photothermal studies have utilized particles with a 120 nm core and 10 nm 
shell, as this corresponds to a peak absorption coefficient in the near infrared range, where 
biological tissue is most permissive to light19,28,32–36.  
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2.2.2.3 Gold Nanorods  !
Gold nanorods are anisotropic nanoparticles composed of solid gold, where particle 
shape strongly influences optical properties. Gold nanorods show a surface plasmon band 
near 520 nm similar to spherical AuNPs, but also have a second band at a longer 
wavelength37. These optical properties are much more dependent on the particle’s aspect 
ratio (ratio of length to diameter)20. The dominant surface plasmon band occurs at a longer 
wavelength, and is based on the axial length of the particle20. The secondary surface plasmon 
band occurs around 520 nm due to the weaker transverse resonance20. Particles with larger 
aspect ratios will have the primary longitudinal resonance at a longer wavelength than 
Figure 2.2. Optical tunability of gold-silica nanoshells. By altering gold-silica core:shell ratios, 
optical tunability can be obtained. A thinner shell causes a red shift in absorbance. Adapted from 
Hirsch et al 200619. 
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particles with a smaller aspect ratio20. These particles can be synthesized either by use of 
rigid templates or, more commonly, by use of seed and growth solutions in the presence of 
surfactants38. 
2.2.3 Gold Nanoparticles in Cancer Medicine !
 Near infrared absorbing gold nanoparticles, particularly gold-silica nanoshells, have 
been investigated for both imaging and therapy applications in cancer medicine. This is due 
to numerous advantageous properties of the particles. First, the outer shell of these particles 
is made of reduced gold, a material known to be biocompatible due to its resistance to 
corrosion and low toxicity19. Second, the size of these particles allows them to be injected 
intravenously and passively accumulate in tumor tissue due to the enhanced permeability and 
retention (EPR) effect39. This phenomenon is observed mainly due to four unique 
characteristics of tumor growth: (1) architectural defects, (2) high vascular density, (3) 
impaired lymphatic drainage, and (4) generation of permeability enhancing factors40. Finally, 
the optical extinction of nanoshells involves both scattering and absorption components. The 
scattering properties of nanoshells can be harnessed for optical imaging of the particles using 
dark field microscopy, optical coherence tomography (OCT), or reflectance confocal 
microscopy (RCM)26,27. In addition, when these particles absorb light, the electron-photon 
interactions within the gold shell yield to heat dissipation and result in photothermal ablation 
of nearby cancer cells19. Photothermal therapy is advantageous for cancer management as 
cell death only occurs where both nanoshell accumulation and NIR light exposure occur, 
minimizing off-site toxicity commonly seen in other cancer treatment modalities.  
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2.2.3.1 in vitro studies !
 Photothermal therapy using gold-silica nanoshells was first demonstrated by Hirsch et 
al. in 200341. In this study, SK-BR-3 human breast carcinoma cells were incubated with 
gold-silica nanoshells and exposed to an NIR laser (820 nm, 35 W/cm2). Results, shown in 
Figure 2.3, show the cells incubated with nanoshells die upon NIR exposure, whereas cells 
without nanoshells retain their viability after irradiation by an NIR laser41.  
 
Figure 2.3. In vitro validation of photothermal therapy. Cells irradiated in the absence of 
nanoshells maintain both viability as determined by Calcein AM staining (A) and membrane integrity 
as demonstrated by a lack of dextran uptake (C). Cells irradiated in the presence of nanoshells shown 
a circular zone of cell death in the Calcein AM image (B) and increased membrane permeability as 
demonstrated by an uptake in fluorescent dextran (D). From Hirsch et al. 200341. !
 Subsequent in vitro studies have focused on active targeting of nanoshells using 
antibodies and other protein based ligands including anti-HER226,42,43, anti-IL13Rα243, and 
ephrinA144. Gold-gold sulfide nanoparticles have also been investigated for photothermal 
therapy potential in vitro, displaying similar results as gold-silica nanoparticles24,45.  
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2.2.3.2 in vivo studies  
 
 Photothermal therapy has been further evaluated in several in vivo studies, most 
commonly in mouse models. In the first study by Hirsch et al., transmissible venereal tumor 
(TVT) cells were inoculated in the hind leg of SCID mice and grown to a diameter of ~1cm41. 
Poly(ethylene glycol) (PEG)-passivated gold silica nanoshells were injected interstitially at 
the tumor site. Nanoshells are often coated with polymer chains such as PEG as this has been 
shown to minimize plasma protein adsorption and therefore increase in vivo circulation time 
of the particles. Next, tumor sites were exposed to 820 nm light at 4 W/cm2, while 
temperature profiles were obtained using phase-sensitive, fast spoiled gradient-echo MRI. 
Results showed an average temperature increase of 9.1±4.7 oC, and gross pathology, as 
shown in Figure 2.4, showed tissue damage and hemorrhaging. 
 
Figure 2.4. Gross histology after photothermal ablation. (A) Gross pathology indicates 
hemorrhaging and loss of tissue birefringence. (B) Silver staining of a tissue section exposes region of 
localized nanoshells (outlined in red). (C) Hematoxylin/eosin staining reveals tissue damage within 
the area occupied by nanoshells. (D) Calculations from MR images further indicate an area of 
irreversible thermal damage. From Hirsch et al. 200341.  
 
Not all tumor sites are amenable to the direct injection of particles into the tumor. 
Recent studies have shown the ability of gold-silica nanoshells to be injected intravenously, 
circulate throughout the body, and accumulate in tumor tissue via the EPR effect. In the first 
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of such studies by O’Neal et al., PEGylated gold-silica nanoshells were injected into the tail 
vein of mice with a subcutaneous tumor46. The tumor was exposed to a 808 nm diode laser 6 
hours post-injection. In addition, a “sham” group received a saline injection followed by laser 
treatment, and a control group received no treatment. Figure 2.5 shows a Kaplan-Meyer 
survival plot for the three groups. All mice that received nanoshell-assisted photothermal 
therapy (NAPT) survived for the 60 day period, whereas the mean survival for the control 
and sham groups were 10.1 days and 12.5 days respectively. Additional in vivo studies have 
shown the potential for nanoshells to be used as both imaging contrast agents for OCT and 
particles for photothermal therapy simultaneously27, as well as a potential treatment for 
malignant glioma47. In addition, gold-gold sulfide particles have also been investigated for in 
vivo photothermal therapy24. 
 
Figure 2.5 Survival curve for NAPT. NAPT mice showed 100% survival after 60 days, while the 
sham and control groups had an average survival of  12.5 and 10.1 days respectively.  From O’Neal et 
al. 200446. 
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 Studies of the biodistribution and clearance of gold-silica nanoshells indicate that the 
particles are primarily cleared via the liver and spleen48. Figure 2.6 shows the biodistribution 
of nanoshells at 24 hours post injection, indicating much higher concentrations in the tumor 
versus most other tissues.  
 
Figure 2.6. Biodistribution of gold nanoshells. Shown are ratios of gold concentration in various 
tissues to that of tumor at 24 hours post nanoshell injection. Tumor tissue displays significantly more 
gold content than all organs excluding the spleen. From James et al. 200748. !
Due to the promise shown in these in vivo studies, photothermal therapy with gold-
silica nanoshells is currently in FDA clinical trials for refractory head and neck cancer49. In 
this treatment, nanoshells are injected to the patient, allowed to passively accumulate in the 
tumor, and then the tumor site is exposed to NIR light from a fiber optic probe49.  
2.3 THERMALLY RESPONSIVE POLYMERS !
The gold-silica nanoshells previously described will provide the stimulus for drug 
release from a polymer coating. Stimuli-responsive ‘smart’ polymers undergo fast, reversible 
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conformational changes in response to small changes in the environment50. Changes in the 
polymer’s conformation usually involve the polymer microstructure transitioning between a 
hydrophilic and hydrophobic state and result in macroscopic material size and properties 
change as well50. Systems responsive to local chemical changes, such as changes in pH, as 
well as systems responsive to external stimuli, such as ultrasound, light, or temperature, have 
been studied51. Temperature-sensitive systems are easy to synthesize and control, making 
them suitable for many applications51. Commonly studied temperature-sensitive polymers 
include acrylamide-based hydrogels, especially poly[N-isopropylacrylamide] (PNIPAAm), 
as well as elastin-like polypeptides (ELPs)50–53. 
At a temperature-sensitive polymer’s lower critical solution temperature (LCST), a 
reversible volume phase transition occurs. At lower temperatures, it is thermodynamically 
favorable for water molecules to form hydrogen bonds with polar groups on the polymer 
chains, causing the hydrogel to be in its swollen state. At higher temperatures, there is an 
increase in Gibbs free energy (ΔG), and hydrogen bonding between the water molecules and 
polymer chains becomes thermodynamically unfavorable compared to polymer-polymer and 
water-water interactions54. This causes the water to move into bulk solution and the polymer 
chains to collapse onto themselves forming hydrophobic interactions55.  A common property 
characterized in thermally responsive systems is the polymer’s deswelling ratio (DSR), a 
measurement of the degree of collapse a hydrogel undergoes at its LCST. 
2.3.1 N-isopropylacrylamide and other acrylamides !
Poly[N-isopropylacrylamide] (PNIPAAm) is a widely studied thermally-responsive 
polymer that exhibits an LCST near physiologic temperatures51. Pure PNIPAAm hydrogels 
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have an LCST range of 25-32oC, and by incorporating a more hydrophilic comonomer into 
the hydrogel, this LCST can be raised to near 45-50oC56. Common comonomers used include 
acrylamide (AAm) or acrylic acid (AAc), with a 95:5 molar ratio of NIPAAm:AAm resulting 
in a gel with an LCST of approximately 40oC29. In addition, incorporation of N-
isopropylmethacrylamide (NIPMAAm) increases the LCST as steric hindrance by the 
additional methyl group inhibits the phase transition57. In contrast, hydrogels consisting of 
hydrophilic acrylamide/acrylic acid monomers exhibit a positive volume change with 
increasing temperatures58,59. A summary of the chemical structures of various acrylamides 
can be found in Figure 2.7. 
 
Figure 2.7. Chemical structures of various acrylamides. !
2.3.1.1 Synthesis of acrylamide-based polymers  !
Radical chain polymerization is commonly used to synthesize acrylamide-based 
polymers. This technique is characterized by being initiated by a reactive species R* 
produced from an initiator I, as shown in Equation 2.1. 
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! → !! ∗                                                        Equation 2.1 
 
The reactive species, commonly a free radical, adds to a monomer molecule by opening the 
π-bond to form a new radical. New monomer molecules are successively added to propagate 
the reactive center, as seen in Equation 2.2. 
 
 
Chain growth is eventually terminated by a reaction with two reactive species.  
Recent advances in radical polymerization focus on controlled radical polymerization 
(CRP) methods, which allow for higher control over molecular weights and end 
functionalities60. There are several different types of CRP techniques, including reversible 
addition-fragmentation chain transfer (RAFT), surfactant-free emulsion polymerization 
(SFEP), and surface-initiated atom transfer radical polymerization (SI-ATRP). These 
techniques are summarized in Table 2.2 below. 
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Table 2.2. Radical Chain Polymerization Techniques61–63. 
 
2.3.2 Elastin-like polypeptides !
Elastin-like polypeptides (ELPs) are synthetic peptides derived from the sequence of 
the hydrophobic domain of tropoelastin64. ELPs generally consist of oligiomeric repeats of 
the pentapeptide VPGXG (where X is any amino acid except proline)64. By using 
recombinant methods to create these polymers, a monodisperse product with little batch-to-
batch variability can be achieved, which is highly advantageous over chemically synthesized 
polymer materials51–53.  By altering amino acid sequence or number of repeats, ELP LCSTs 
(also commonly called transition temperatures, or Tt) are highly tunable and can be brought 
to above physiologic temperatures52,53. ELPs are synthesized by creating the genetic 
WIREs Nanomedicine and Nanobiotechnology Polymer–nanoparticle composites for biomedical applications
TABLE 2 Polymerization Processes64–66
Surfactant-Free Emulsion
Polymerization (SFEP)
–polymerization initiator 
soluble in aqueous phase, 
polymer forms in oil phase
–polymerization occurs at 
oil-water interface
Reverse-Addition
Fragmentation 
Polymerization (RAFT)
–requires initiator in presence
of chain-transfer agent
–living polymerization
technique
Surface Initiated-Atom 
Transfer Radical
Polymerization (SI-ATRP)
–requires a transition metal
catalyst, nitrogen-based ligand,
and alkyl-halide
+
Aqueous phase
Monomer
I R′
R′
Polymer
(oil phase)
(1)
(2)
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S
M
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S
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S S
R′
S S
R
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M = Transition metal
L = Nitrogen-based ligand
X = Br or Cl
complete hydrogel coating.26 energy dispersive x-ray
spectroscopy (EDX) analysis showed large peaks indi-
cating gold atoms as well as no peaks for the hydrogel
polymer, as predicted given the low atomic numbers
of the hydrogel elements.26 Higher resolution trans-
mission electron microscopy (TEM) images show the
complete hydrogel shell growth around the particle,
as well as differences in hydrogel thickness that could
be obtained by minor variations in the monomer and
initiator amounts as well as reaction time.26 How-
ever, one drawback of this polymerization method is
the encapsulation of multiple particles into one hydro-
gel matrix.26 UV–Vis spectroscopy showed minimal
changes in the absorption profile of the bare silica–Au
nanoshells and hydrogel-coated n noshells. Dynamic
light scattering (DLS) studies show that the hydrody-
namic radius of the hydrogel particles decreasing with
increasing temperature, an indication of collapse of
the hydrogel. The results of this study are summarized
in Figure 6.
SI-ATRP Methods
Synthesis of a hydrogel coating using SI-ATRP has
also been investigated for its tight control over the
thickness of gel produced, providing monodisperse
particles. Wei et al. used this method to create a
PNIPAAm coating on NIR-absorbing AuNRs.60 This
study used AuNRs with an aspect ratio of 4.4 ±
0.4 and a peak longitudinal plasmon resonance of
843 nm. A disulfide initiator was immobilized onto
the AuNR surface followed by in situ polymerization
of PNIPAAm. TEM characterization of the particles
showed that a core/shell structure was formed, and
it was noted that the thickness of the coating could
be tuned by the polarity of the solvent, with more
polar solvents yielding thicker coatings. DLS showed
an increase in hydrodynamic diameter at temperatures
from 32 to 37◦C, indicating the hydrogel coatings had
collapsed and become more hydrophobic, causing
the particles to precipitate out of solution and
aggregate. In addition, a drug-loading experiment
with norvancomycin, an antibiotic, showed increased
release when the particles were irradiated with an
808 nm laser.
This method has also been employed using iron
oxide nanoparticles. Frimpong et al. demonstrated
growth of a PNIPAAm hydrogel with poly(ethylene
glycol) 400 dimethacrylate (PEG400DMA) cross-links
using SI-ATRP on iron oxide particles of 6–10 nm
Volume 3, May/June 2011  2011 John Wiley & Sons, Inc. 313
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sequence that encodes these repetitive polypeptides, inducing expression of that sequence in 
E. coli, and then purifying the peptide product. This is commonly done through a process 
known as recursive directional ligation (RDL), which allows the synthesis of large, repetitive 
genes52.  
2.3.3 Thermally-responsive polymers in cancer medicine  !
 Many of the first comprehensive studies of a thermally responsive polymer being 
used in a cancer medicine studies come from the Chilkoti group53,65–71. The first of such, 
published in 2001, showed that ELPs conjugated to drugs could be thermally targeted to solid 
tumors65. ELPs were designed to have a Tt of ~41oC, with the hypothesis that these particles 
would remain soluble in solutions below their Tt (such as at physiologic temperature), but 
then become insoluble and aggregate at solution temperatures above 41oC. These particles 
could then be injected and would circulate throughout the body at 37oC, however, if localized 
hyperthermia treatments were used to heat a solid tumor, these particles would become 
insoluble and aggregate in the tumor. For this study, ELP-rhodamine conjugates were 
injected in nude mice with human SKOV-3 ovarian carcinoma tumors with four study 
groups: (1) ELP1, designed to have a Tt at 41oC, injected with tumor heating, (2) ELP1 
injected without tumor heating, and (3) ELP2, designed with a high Tt to remain soluble at 
temperatures above 42oC, with tumor heating, and (4) ELP2 without tumor heating. The 
results, illustrated in Figure 2.8, show a ~2 fold increase in tumor localization for group 1 
compared to group 2, and significantly more accumulation for group 1 compared to all other 
groups (p<0.001)65.  Additional studies by the Chilkoti group68 yielded similar results and 
demonstrated that thermal cycling of the tumor between 37oC and 41oC further enhances 
ELP accumulation69. 
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Figure 2.8. Tumor localization of ELPs. Expressed as percentage of the injected dose per gram of 
tissue. Tumor localization is significantly greater for the thermally responsive carrier (ELP1) when 
the tumor was heated to 42 oC compared to the other 3 groups (p<0.001).  From Dreher et al. 200769. !
A similar study compared the ability to target both thermally responsive ELPs and 
thermally responsive poly(NIPAAm-co-AAm) to tumors53. In this study, both the ELP and 
poly(NIPAAm-co-AAm) used were tuned to have an LCST at 40oC. This was accomplished 
by substituting Ala and Gly residues for the more hydrophobic Val at the fourth position of 
the ELP pentipeptide, and by using an 84:16 ratio of NIPAAm:AAm in the poly(NIPAAm-
co-AAm). In addition, a control ELP and polymer were made to have an LCST above 42oC, 
and therefore remained soluble even in the heated tumor. Results, shown in Figure 2.9, 
indicate that heating did increase accumulation of both thermally responsive carriers in the 
tumor compared to controls. However, the ELP displayed enhanced accumulation in tumors 
over the polymer. The authors speculate that this may be because the LCST of 
poly(NIPAAm) and its copolymers can only be tailored to a limited extent by altering 
incorporation of co-monomers, chain length, sequence, and stereochemistry, whereas ELPs 
genetic control allows for more precise tuning of chemical properties such as transition 
temperature53.  
within the heated tumor. Studies on the mechanism via which the
ELPs interact with endothelial and tumor cells as a function of
temperature are currently in progress to elucidate the origin of this
effect.
We also independently studied thermal targeting of the ELP carrier
by directly determining the localization of radiolabeled ELP in im-
planted tumors, with and without hyperthermia. Fig. 10 shows that
tumor localization of the thermally responsive ELP1 was 80% greater
for the animals that received the hyperthermia treatment than for the
same ELP in unheated tumors (P ! 0.01). Unlike the window cham-
ber experiment, the data for the high temperature control were ob-
tained from the same animals using coinjected, paired radiolabels. For
animals treated with hyperthermia, tumor accumulation of ELP1 (with
Tb ! Tt ! Th) was 34% greater than that for ELP2 (for which
Tt " Th; P ! 0.005). From the combined data of the two controls, we
conclude that#60% of the total increase in ELP1 tumor accumulation
versus the nonheated group can be attributed to the effects of the ELP
inverse transition, and #40% is contributed by the physiological
effects of hyperthermia. It is notable that the percentage increase in
tumor accumulation of the heated, thermally responsive carrier versus
both controls in the radiolabel distribution experiments is consistent
with the results from the quantitative analysis of the window chamber
experiments. Finally, there was no significant difference in tumor
localization between ELP1 and ELP2 for the unheated control group,
indicating that the thermally responsive and unresponsive carriers
behaved similarly in the absence of heat. This demonstrates that
ELP2, with its composition and molecular weight virtually identical to
those of ELP1, is a well-designed, thermally unresponsive control.
The controls for the experiments described here were carefully
designed to elucidate the separate effects of changes in tumor phys-
iology due to hyperthermia and of the thermally triggered phase
transition of the ELP on localization of the carrier in solid tumors.
These controls should also prove useful in future optimization studies
seeking to maximize the effect of the phase transition on tumor
accumulation of the carrier. However, it is critical that the results of
the current study be viewed in the context of drug delivery using
macromolecular carriers. The observed #2-fold increase in ELP1
accumulation in heated tumors is not relative to free drug. Soluble
macromolecular carriers can provide up to several orders of magni-
tude greater delivery and specificity (e.g., passive tumor targeting due
to the enhanced permeability and retention effect) to the tumor versus
free drug (1, 6), particularly for low molecular weight drugs with
rapid renal clearance and for hydrophobic drugs with low solubility.
Therefore, the increase in tumor delivery due to the ELP inverse
temperature transition should be viewed as a synergistic factor that
further amplifies the advantages of using macromolecular carriers to
deliver drugs to solid tumors.
Although other thermally responsive drug carriers such as temper-
ature-sensitive liposomes and cross-linked hydrogels have been pro-
posed (27–29), to our knowledge, this is the first reported use of a
thermally responsive polymer as a soluble carrier for thermal drug
targeting. One advantage of this system over other thermally respon-
sive carriers is that accumulation of the drug in the target tissue is
driven through a phase transition of the carrier rather than through
thermally triggered release of the drug. A concentration gradient is
therefore not required to drive accumulation of the ELP, which will
continue to accumulate through phase separation in a heated tumor
(provided that Tt ! Th) even when their blood concentration is less
than the concentration in the tumor. This is an attractive feature
because it enables the ELP-drug conjugate to be injected at a lower
and therefore less toxic systemic concentration while still achieving a
higher therapeutic concentration in the tumor.
Thermal targeting achieves regional targeting and is not specific to
a particular cell type; therefore, any organ or tissue can be targeted
independent of the availability of specific ligands or antibodies. For
the delivery of radiotherapeutics, regional targeting (i.e., targeting to
the tumor as opposed to tumor cells) is sufficient for therapy, and our
initial work is therefore focused on their delivery to solid tumors.
However, the delivery of other molecules such as chemotherapeutics,
oligonucleotides, or imaging agents may require tumor cell-specific
targeting. For these applications, thermal targeting could be synergis-
tically combined with a cell-specific affinity-targeting moiety by gene
level fusion or chemical conjugation of the targeting moiety (30–32).
Alternatively, the ELP could serve as a first stage, systemic targeting
method to rapidly increase concentrations in the targeted region. This
would be followed by release of the drug through labile linkers, which
could also incorporate a secondary, affinity-targeting molecule.
The results presented here should be viewed as preliminary because
no attempt has yet been made to optimize important experimental
variables. In future studies, the ELP molecular weight is likely to be
the most important design criterion to be explored because it is the
primary design parameter that controls both plasma half-life and
extravasation. The systemic concentration of the drug-ELP conjugate
Fig. 9. Fluorescence intensity of vasculature (!) and interstitium (E) in the window
chamber as a function of time after injection of ELP1-rhodamine conjugate in the heated
tumor (mean $ SE; n % 5). Accumulation of ELP1 increased through the course of the
experiment for both regions, although the interstitial intensity grew more rapidly, sug-
gesting that increased extravasation is an important factor leading to tumor localization.
Fig. 10. Tumor localization of radiolabeled ELP (mean $ SE; n % 5), expressed as a
percentage of the injected dose per gram of tissue. Tumor localization was significantly
greater for the thermally responsive carrier (ELP1) when the tumor was heated to 42°C
than for the same carrier in the low temperature controls (P ! 0.01, unpaired, nonpara-
metric Mann-Whitney test). Within the heated group, the thermally responsive ELP
accumulated to a significantl great r level as compared with the thermally unresponsive
control (ELP2; P ! 0.005, paired t test). There was no significant difference between
ELP1 and ELP2 within the low temperature control group.
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Figure 2.9. Tumor accumulation of ELPs and polymer carriers. Total fluorescence intensity for 
ELP and polymer carriers at 44 and 26 minutes post-injection, respectively. Carrier 1 was the 
thermally responsive carrier (LCST ≈ 40 oC) and Carrier 2 was the control carrier (LCST > 42 oC). 
From Meyer et al. 200153. !
 In a study by Dreher et al., the chemotherapeutic doxorubicin (dox) was conjugated 
to ELPs through an acid-labile hydrazine bond, aimed to release the drug within the acidic 
environment of lysosomes66. Further optimization of ELP-dox conjugates analyzed the 
effects of: (1) the site of dox attachment to the ELP, (2) different acid-labile bonds for 
optimal release, and (3) design of a linker in which the acid labile bond is embedded67. It was 
found that the attachment to the C-terminal cysteine residue was optimal. Linker structure 
seemed to have little effect on the Tt of the ELP, but the shortest linker tested displayed the 
highest release of dox at ~80% released at 72 hours at pH 467. 
 A study by MacKay et al. analyzed the in vivo efficacy of an ELP-like drug carrier 
loaded with doxorubicin70.  These carriers, called chimeric polypeptides (CPs) consisted of 
two segments: a biodegradable ELP segment and a short segment for the attachment of dox. 
220 D.E. Meyer et al. / Journal of Controlled Release 74 (2001) 213–224
such particles were observed in any of the heated or selected for the ELP and poly(NIPAAm–co-AAm)
unheated control animals for either carrier. The carriers to illustrate the enhancement of tumor
aggregates often attached to the vessel wall, and accumulation that can be achieved by each system.
grew in intensity and size over time. In some At 44 min post-injection, the total window intensity
instances, the particles were sheared from the vessel increased by |250% for heated ELP1 relative to its
walls and carried away by the blood flow. Because initial window intensity, indicating significant ac-
the LCST transition is completely reversible, any cumulation of the carrier occurred over time. After
particles washed from the heated tissue would be 26 min, pNIPAAm1 had similarly increased 180%
expected to rapidly disaggregate and resolubilize. relative to its initial window intensity. Total accumu-
The presence of these aggregates only in the heated lation for the thermally responsive carriers was |2-
window chamber provides clear evidence that the fold greater than that for the heated and unheated
LCST can be engineered to occur at a specific LCST control groups (P,0.05 for heated pNIPAAm1
even in the complex solution environment within the versus both control groups and for ELP1 versus the
body. Accumulation of the thermally responsive unheated control group; P,0.1 for heated ELP1
carriers (ELP1 and pNIPAAm1) in heated tumors versus the heated ELP2 control group). The vid-
increased with time, and by 30 min, extravascular eomicroscopy results (Fig. 3A and B) suggest that
areas of the window often became so bright that they the observed increases in total window intensity in
were indistinguishable from vessels (Fig. 3A and B). heated tumors of the thermally responsive carriers
We also quantified the accumulation of the carriers was due both to increased extravasation of the
in the tumors by digital analysis of the whole thermally responsive polymer and to accumulation of
window fluorescence intensity. Fig. 4 shows the aggregated carrier in the vasculature.
average intensity of the window at 44 min (ELP
carriers) and 26 min (poly(NIPAAm–co-AAm) nor-
malized to the initial intensity (at 30 s post-injection) 4. Discussion
for each of the six groups. Because they exhibited
different pharmacokinetics (likely due to their differ- The polymers described here undergo a thermo-
ent molecular weights), separate time points were dynamically reversible LCST transition that occurs
when waters of hydration surrounding the polymer
are released to the bulk through hydrophobic col-
lapse of the polymer, leading to polymer aggregation
and separation from the aqueous phase. Although the
LCST behavior of both polymer systems is thermo-
dynamically similar, each polymer system has dis-
tinct advantages and disadvantages as a carrier for
therapeutics. Because they are polypeptides, ELPs
are genetically encodable, which provides exquisite
control over their sequence and physicochemical
properties. Genetically encodable synthesis also en-
ables genetic fusion to other tumor-specific protein
or peptide targeting moieties or therapeutics to be
easily achieved with stoichiometric yield. In contrast,
poly(NIPAAm) is a synthetic polymer, and canFig. 4. Total window fluorescence intensity for the ELP and
poly(NIPAAm–co-Am) carriers at 44 and 26 min post-injection, therefore be inexpensively produced in large quan-
respectively, after background correction and normalization to the tities compared to ELPs. Although the properties of
initial intensity (median6IQR, n55). Accumulation of the ther- poly(NIPAAm) and its copolymers can be tailored tomally responsive carriers in heated tumors was |2-fold greater some extent by the incorporation of co-monomers,than the heated and unheated control experiments for both their sequence, chain length, and stereochemistrypolymers (P,0.1 versus the heated ELP control, P,0.05 for all
others). cannot be controlled to the extent possible with
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These particles self-assemble into sub-100 nm nanoparticles upon drug attachment, as 
demonstrated in Figure 2.1070.  
!
Figure 2.10. Self-assembly of chimeric polypeptides. The hydrophobic drug triggers self assembly 
into a particle with a drug rich core (red triangles) surrounded by hydrophilic polypeptide corona 
(blue chains). From MacKay et al. 200970.  !
These particles were injected into a mice BALB/c subcutaneous mouse tumor model via a 
tail vein injection (5 mg doxorubicin equivalent/kg).  Tissue biodistribution of the particles 
was analyzed at both 2 and 24 hours post-injection. After 24 hours post administration, tumor 
tissue had a 3.5-fold increase in dox concentration for the CP-dox group compared to the free 
dox group. In addition, the CP-dox group showed decreased dox concentration in several 
tissue sites known to be adversely affected by dox including the muscle, lung, and heart70. A 
survival analysis of mice receiving either CP-dox or free dox found that CP-dox treatment 
cured 8 of 9 mice for up to 66 days post tumor implantation, while the median survival for a 
PBS injection (control) was 21 days and for free dox administration was 27 days70. It is 
interesting to note that this study did not utilize the thermal properties of the CP particles, as 
the tumor was not heated as had been done in previous studies. Further studies from the 
Chilkoti group have looked at ELP-radionuclide conjugate effects of tumor progression71. 
Additionally, other groups have looked at ELPs as delivery vehicles for short peptides to 
disrupt transcriptional functions72. 
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2.4 THERMALLY RESPONSIVE POLYMER-NANOPARTICLE COMPOSITES  !
Thermally responsive polymer-metal nanoparticle composites couple the ability of 
metal nanoparticles to convert external stimuli to heat with polymers that display sharp 
property changes in response to temperature changes, allowing for external control over 
polymer properties. These systems have been investigated for a variety of biomedical 
applications, including drug delivery, microfluidic valve control, and cancer therapy. Three 
size scales of this system have been investigated: bulk systems (>1 mm), nano/micro scaled 
systems, and individual particle coatings. Previous studies of such systems relating to 
biomedical applications are discussed in this section. 
2.4.1 Bulk Systems !
Several systems incorporating bulk hydrogels (diameter >1 mm) with encapsulated 
nanoparticles have been investigated for applications including drug delivery29,30,35,73, 
microfluidic33,34,74 and microlens75 control. Additionally, the effects of these encapsulated 
nanoparticles on polymer bulk properties have been studied76,77. 
Drug delivery applications using both near-infrared absorbing nanoparticles and iron 
oxide nanoparticles are of interest. By combining thermally responsive polymers with 
encapsulated nanoparticles, drug release can be triggered by an external stimulus,  A 
schematic of this process is shown in Figure 2.11. 
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Figure 2.11. Schematic of drug delivery from bulk hydrogels. 
 
Photothermally modulated drug delivery was first shown by Sershen et al. using a 
combination of N-isopropylacrylamide-co-acrylamide (NIPAAm-co-AAm) and gold-gold 
sulfide nanoparticles29. This study used hydrogels with a 95:5 molar ration of 
NIPAAm:AAm to achieve an LCST slightly above physiologic temperature. Upon NIR 
irradiation of these composites, the temperature of the hydrogel exceeds the LCST causing a 
burst release of any soluble molecules contained in the hydrogel matrix. Enhanced release of 
molecules such as methylene blue, ovalbumin, and bovine serum albumin was found to 
follow near infrared irradiation of the nanoparticle-composite hydrogels29.  Further 
investigation of this system showed that it could be applied to photothermal delivery of 
insulin30.  
A system using the same NIPAAm:AAm hydrogel formation with gold-silica 
nanoshells also successfully demonstrated photothermal drug delivery35. Studies showed that 
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the collapse of hydrogel-nanoshell composites was controlled by both laser fluence and SiO2 
nanoshell concentration35. Photothermal release studies of methylene blue, insulin and 
lysozyme showed a pulsatile drug release that was dependent on the molecular weight of the 
molecule35. 
Magnetic iron oxide particles embedded in a NIPAAm- based matrix73,78–80 have also 
been investigated for use as a drug delivery system, Bulk hydrogels were created using 
tetra(ethylene glycol) dimethacrylate (TEGDMA)73,80 or poly(ethylene glycol) 400 
dimethacrylate (PEG400DMA)79 as a crosslinking agent. The incorporation of varying 
concentrations of iron oxide particles (20-30nm diameter) showed no effect on swelling 
characteristics of the hydrogels78.  These hydrogel discs were found to increase in 
temperature and then collapse following exposure to an alternating magnetic field (AMF)73,79. 
A burst release of absorbed methylene blue or vitamin B12 followed pulse application of 
AMF, with minimal diffusion of the particles out of the matrix without AMF73. This study 
discussed that such a composite could potentially be used as a implanted, remotely controlled 
drug delivery device73. 
2.4.2 Nano/Micro Scale Composites and Micelles !
While the majority of applications in this field focus on either bulk (>1mm) hydrogels 
or nanoscale coatings, a few groups have looked at micro-sized applications and micelles. 
Investigations have focused mostly on electrical and sensor properties of these materials81–83 
as well as their potential for drug delivery84,85. 
A study by Kim et al. proposed combining hybrid AuNP/iron oxide NPs with a 
poly[N-isopropylacrylamide-co-acrylamide]-block-poly[ε-caprolactone] for combined 
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hyperthermia and chemotherapy delivery with optical imaging84. This study used an 86:14 
NIPAAm:AAm ratio to achieve an LCST of 42-45oC. Initial results showed that the 
hydrodynamic diameter of these micelles decreased from 104 nm to 71 nm when temperature 
was increased from 25oC to 45oC. Further optical and magnetic studies and characterization 
of this system are ongoing84. 
Hoare et al. developed a membrane-based drug delivery system consisting of an ethyl 
cellulose-iron oxide particle nanocomposite membrane with embedded PNIPAAm-based 
hydrogels, as shown in the schematic in Figure 2.1285. By applying an oscillating magnetic 
field to this device, the heat increase caused the nanogel to deswell, allowing a “strong flux” 
of drugs out of the reservoir. This device was synthesized by coevaporation caus entrapment 
of PNIPPAm nanogels and iron oxide nanoparticles in the cellulose membrane. The 
PNIPAAm gel was engineered to have an LCST above physiologic temperature by 
incorporating NIPMAAm as well as AAm.  Analysis with sodium fluorscein showed a ~20 
fold increase in flux when the device was turned “on” by exposure to an oscillating magnetic 
field, as well as consistent drug flux over four on-off cycles. The authors noted that the rapid 
swelling kinetics due to the size and engineered phase-transition behavior of the nanogels as 
well as the optimized size and surface chemistry of the iron oxide nanoparticles allowed for 
rapid, repeatable, and tunable drug release under physiological conditions85. 
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Figure 2.12. Schematic of drug delivery from magnetically triggered nanogel composite 
membranes. From Hoare et al. 200985. 
 
2.4.2.1 Thermally Responsive Liposomes  !
 Heat sensitive liposomes have been investigated for drug delivery applications, with 
some formulations reaching clinical trials86. Recent work by Qin et al. aimed to combine a 
heat sensitive liposome with gold nanoparticles attached to the surface87.  The characteristics 
of this system are described in Figure 2.13 below. 
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Figure 2.13. Properties of thermally responsive lipsome-gold nanoparticle system. (a) Schematic 
of drug release process. (b) UV-vis absorption spectrum of the gold nanoparticles used. (c) Cryo-
TEM image of a liposome tethered to a gold nanoparticle (d) Cryo-TEM image of a liposome-
nanoparticle complex after irradiation with a 532 nm laser. From Qin et al. 201187.  
 
This system was tested with doxorubicin and was found to retain the encapsulated drug at 
40oC for 3 days and instantaneously release over 70% of the encapsulated drug upon 
exposure to a 532 nm laser. Further research is being done to tether hollow gold nanoshells, 
which have a surface plasmon peak in the near infrared range, instead of solid gold 
nanoparticles, to allow the system to be used in clinical applications87. Other groups have 
looked at remote control release from thermosensitive liposomes by injections of both 
liposomes and gold nanorods88.  
2.4.3 Polymer Coated Nanoparticles !
As of late, much focus has been placed on ways to apply a thermally-responsive 
hydrogel coating on individual nanoparticles. This would allow particles to retain their size 
while gaining the drug delivery potential of PNIPAAm based systems discussed previously. 
Several synthesis methods have been investigated for this application including reversible 
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Figure 3. (a) Illustration of the releasing process; (b) UV–vis absorption spectrum of gold nanoparticles (GNPs); (c) a typical cryo-EM image
of a PPL tethering a GNP; and (d) a typical cryo-EM image showing PPL/GNP complexes after laser irradiation. The scale bar in (c) also
applies to (d).
(This figure is in colour only in the electronic version)
demonstrated that PPLs are remarkably stable at the upper-
limit of physiologic body temperature long enough for most
in vivo targeted drug delivery schemes.
To demonstrate the controllability of releasing encapsu-
lated content from the stable PPLs, we utilized a laser to
excite the gold nanopar icles tethered to the PPLs through
surface plasmon resonance. The release of encapsulated
content was induced by the laser energy absorbed by the
gold nanoparticles [29–32], and Wu et al has demonstrated
that the gold nanoparticles tethered on the outer surface of
liposomes released the most of their contents [33]. Therefore,
we incubated PPLs with a suspension of GNPs (50 nm) at
room temperature for 1 h. The attachment of GNPs to
PPL is shown in figure 3. The gold nanoparticles were
chosen to have a nominal diameter of 50 nm and a maximum
absorption at 532 nm (figure 3(b)) that matches the wavelength
(λ0 = 532 nm) of a Nd:YAG laser (Brilliant B, Quantel Inc.).
Furthermore, the absorption spectrum of PPL/GNP complexes
also showed strong absorption at 532 nm, consistent with the
laser wavelength (figur S2, supporting information available
at stacks.iop.org/Nano/22/155605/mmedia). We irradiated the
sample with 10 × 6 ns pulses of the laser (10 Hz frequency,
intensity up to 400 mJ/pulse, corresponding to a mean power
density of 3.3 W cm−2). Upon laser irradiation, the remaining
radioactivity inside the liposomes could be precisely quantified
by using a Bioscan radio detector incorporated with a liquid
chromatography (LC) system. The results showed that ∼70%
of the content was released from the gold nanoparticle tagged
PPLs (PPL/GNP) by the laser irradiation (figure 4). In
contrast, less than 3% of the encapsulated content was released
from the control PPLs without gold nanoparticles after laser
irradiation, demonstrating that the gold nanoparticles present
on the liposomes are necessary for laser triggered release.
To further demonstrate that the release of liposomal
content was indeed induced by the gold nanoparticles
Figure 4. Content release from PPLs and PPL/GNP complexes upon
laser irradiation with a wavelength of 532 or 1064 nm for ten pulses.
(n ! 3.)
upon absorption of laser energy corresponding to the
peak absorption wavelength of the gold nanoparticles, the
experiment was repeated using a laser with a wavelength of
1064 nm (6 ns duration, 10 Hz frequency, intensity up to
800 mJ/pulse, corresponding to a mean power density of
6.6 W cm−2). Our data showed that both PPL/GNPs and PPLs
released less than 5% of encapsulated content upon irradiation
with 10 pulses of the laser with a wavelength far from the peak
absorption wavelength of the gold nanoparticles (figure 4).
The morphological changes of PPLs and PPL/GNPs
induced by pulsed laser irradiation were also investigated
by Cryo-EM. No morphological changes were observed
for the unlabeled liposomes after laser irradiation. In
contrast, for PPL/GNP carriers, the 50 nm GNPs were
fragmented into smaller particles with a diameter of less than
4
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addition-fragmentation chain transfer (RAFT)89–92, surfactant-free emulsion polymerization 
(SFEP)36,93,94, surface initiated-atom transfer radical polymerization (SI-ATRP)95–97, and 
other methods98,99.  
2.4.3.1 SFEP Methods !
The work of Kim et al. investigates SFEP of poly(NIPAAm-co-AAc) onto AuNP and 
silica-Au nanoshells for drug delivery applications36,93,94.  This synthesis method used a 94:6 
wt% ratio of NIPAAm:AAc and N,N-methylenebisacrylamide (BIS) as a crosslinking agent. 
This process was carried out on 60 nm AuNP93 and silica-Au nanoshells36. In addition, 
studies using a SFEP poly(NIPAAm-co-AAc) as a template for the growth of large (60-
150nm) AuNP have also been investigated94. In the study utilizing gold-silica nanoshells, FE-
SEM images showed uniform particle sizes as well as contrast effects showing particle cores 
with a complete hydrogel coating36. Energy-dispersive x-ray spectroscopy (EDX) analysis 
showed large peaks indicating gold atoms as well as no peaks for the hydrogel polymer, as 
predicted given the low atomic numbers of the hydrogel elements. Higher resolution TEM 
images show the complete hydrogel shell growth around the particle, as well as differences in 
hydrogel thickness that could be obtained by minor variations in the monomer and initiator 
amounts or reaction time. However, one drawback of this polymerization method is the 
encapsulation of multiple particles into one hydrogel matrix. UV-Vis spectroscopy showed 
minimal changes in the absorption profile of the bare Silica-Au nanoshells and hydrogel 
coated nanoshells. DLS studies showed that the hydrodynamic radius of the hydrogel 
particles decreased with increasing temperature, an indication of collapse of the hydrogel. 
The results of this study are summarized in Figure 2.1436. 
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Figure 2.14. Hydrogel coating by surfactant-free emulsion polymerization (SFEP). [A] TEM 
images of (a) bare nanoshells (diameter~120 nm); (b) thin hydrogel-coated nanoshells (diamter~160 
nm); (c) thick hydrogel-coated nanoshells; and (d) multiple encapsulated nanoshells. [B] UV-Vis 
spectra of gold-seeded silica cores, bare nanoshells, and hydrogel coated nanoshells. [C] 
Hydrodynamic diameters of bare nanoshells and hydrogel-coated nanoshells as a function of 
temperature. Adapted from Kim et al. 200836.  
 
2.4.3.2 SI-ATRP Methods !
Synthesis of a hydrogel coating using SI-ATRP has also been investigated due to its 
tight control over the thickness of gel produced, providing for monodisperse particles. Wei et 
al. used this method to create a PNIPAAm coating on NIR absorbing AuNRs96. This study 
used AuNRs with an aspect ratio of 4.4±0.4 and a peak longitudinal plasmon resonance of 
843 nm. A disulfide initiator was immobilized onto the AuNR surface followed by in situ 
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polymerization of PNIPAAm. TEM characterization of the particles showed a core/shell 
structure was formed, and it was noted that the thickness of the coating could be tuned by the 
polarity of the solvent, with more polar solvents yielding thicker coatings. DLS showed an 
increase in hydrodynamic diameter at temperatures from 32-37oC, indicating the hydrogel 
coatings had collapsed and become more hydrophobic, causing the particles to precipitate out 
of solution and aggregate.  In addition, a drug loading experiment with norvancomycin, an 
antibiotic, showed increased release when the particles were irradiated with an 808 nm laser96.  
 This method has also been employed using iron oxide nanoparticles. Frimpong et al. 
demonstrated growth of a PNIPAAm hydrogel with poly(ethylene glycol) 400 dimethacrylate 
(PEG400DMA) crosslinks using SI-ATRP on iron oxide particles of 6-10 nm diameters95. 
First, the particles were coated with either oleic acid or citric acid followed by a ligand 
exchange reaction with bromine alkyl halides and a bromo-saline to act as initiators of the 
ATRP reaction of poly(NIPAAm-PEG400DMA). High resolution TEM analysis showed an 
ordered crystalline core next to an amorphous polymer shell less than 5 nm thick. DLS 
analysis showed a larger hydrodynamic diameter of these particles at temperatures from 20-
30oC with smaller hydrodynamic diameters observed at temperatures above the hydrogel 
LCST95.   
 
2.4.3.3 Elastin-like polypeptide coatings !
Huang et al. developed an optically responsive ELP-gold nanorod system100. A novel 
22 kDa cysteine containing ELP was conjugated to NIR absorbing gold nanorods by gold-
thiol bonds103. The transition temperature (Tt) of the ELP was determined to be 33.4oC; 
above this temperature the particles aggregated together resulting in an increase in optical 
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density.  NIR irradiation of these particles resulted in an optical response due to a 
conformational change in the ELP100.   
2.5 CONCLUSION !
In the current literature, there is no report of an optically triggered thermally responsive 
polymer-nanoparticle drug delivery system that has been successfully tested in vivo.  This 
thesis builds on the successful results from previous studies to create such a platform. This 
delivery platform was synthesized using two material components: a thermally responsive 
poly(NIPAAm-co-AAm) hydrogel and embedded gold-silica nanoshells. The controlled 
delivery system being proposed in this thesis aims to provide burst delivery of a cancer 
therapeutic only at the site of malignant tissue. 
  To begin, Chapter 3 of this thesis describes the synthesis and characterization of bulk 
poly(NIPAAm-co-AAm)-gold nanoshell composites. In Chapter 4, these composites are 
loaded with cancer therapeutics, and release is demonstrated to follow NIR light exposure. 
Chapter 5 describes methods being used to synthesize this platform as nanoscale-sized 
particles.  Finally, Chapter 6 summarizes these results and discusses future optimization of 
this platform.  
!!!!!
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3 SYNTHESIS OF BULK HYDROGEL-NANOSHELL COMPOSITES !
3.1 INTRODUCTION !
This chapter presents the methods used throughout this thesis to synthesize and 
characterize gold-silica nanoshells, poly(NIPAAm-co-AAm) hydrogels, and hydrogel-
nanoshells composites. This material was designed such that it would be swollen in 
physiologic state, but would collapse in response to NIR exposure.   
3.2 GOLD-SILICA NANOSHELL SYNTHESIS 
  
To synthesize gold-silica nanoshells, silica cores are created using the Stöber method 
and then surface functionalized with amine groups using silane reagents. Small gold colloid 
particles (~2 nm) were then absorbed onto the aminated surface to form gold nucleation 
sites19. A final reduction step in chloroauric acid, potassium carbonate, and formaldehyde 
produced a gold shell between 5-30 nm thick18. This synthesis process is summarized in 
Figure 3.1, accompanied by a TEM micrograph depicting shell growth31.  
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Figure 3.1. Gold-silica nanoshell synthesis. [A] The four steps of gold-silica nanoshell synthesis: 
(1) formation of silica core, (2) amine functionalization, (3) absorption of gold colloid and (4) shell 
growth. [B] TEM image depicting shell growth on a silica core from absorbed gold colloid. Adapted 
from Oldenburg et al. 199831. !
For the first step of silica core formation via the Stöber method101, tetraethyl 
orthosilicate (TEOS) was reduced in ethanol (EtOH) in the presence of ammonium hydroxide 
(NH4OH). To achieve core diameters of approximately 120 nm, 0.5 g of NH4OH (Aldrich, 
28%) was added to 32.06 g 200 proof EtOH. With rapid stirring, 1.69 g of TEOS (Aldrich, 
99.999%) was added. The reaction mixture was rocked overnight at room temperature. The 
following day the cores were washed by three rounds of centrifugation (2500g, 30 min) and 
suspended in EtOH. Scanning electron microscopy (SEM, FEI Quanta 400 FEG) was used to 
determine core diameters and polydispersity. Cores with a diameter of ~120 nm and 
polydispersity of <10% were used in subsequent steps. Silica cores were then functionalized 
with amine groups via a reaction with aminopropyltriethoxysilane (APTES). For every 1 ml 
of cores at 4 wt%, 5 µl of APTES (Gelest) was added under rapid stirring and allowed to 
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react overnight at room temperature. The following day, the reaction solution was boiled for 
2 h to ensure surface exposure of amine groups. The solution was then centrifuged for 3 
rounds (2500xg, 30 min) and resuspended in EtOH.  
Colloidal gold particles with a 2-4 nm diameter were prepared by a reduction of 
chloroauric acid (HAuCl4) as previously described in the literature102. A solution of 
tetrakis(hydroxymethyl)phophonium chloride (THPC, TCI America, 80%) in water was 
created by mixing 400 µl of THPC with 33 ml millipore H2O.  Next, 4 ml of this THPC 
solution was added to 1.2 ml of 1 N sodium hydroxide (NaOH, Aldrich) and 180 ml of 
millipore H2O. This solution was rapidly stirred for at least 5 min, and then 6.75 ml of 1% 
HAuCl4 (Alfa Aesar, 99.999%) was added. The solution was stirred until the solution color 
stabilized (<1 min) and the product was stored at 4 oC. This colloid solution was aged for at 
least 2 weeks before being used in subsequent steps.  
Aminated silica cores were then mixed with this gold colloid suspension to create 
“seed” particles with the colloid being absorbed onto the silica core via electrostatic 
interaction between the positively charged amine group and negatively charged colloid.  For 
this reaction, 30 ml of colloid suspension was mixed with 180 µl functionalized cores and 1 
ml 1 M NaCl. The reaction mixture was rocked for at least 48 h at room temperature and 
washed by two rounds of centrifugation (1500xg, 30 min) and resuspended in H2O. 
Nanoshell synthesis was completed by a shell growth step. A gold plating solution 
was made by combining 200 mg of potassium carbonate (K2CO3), 12 ml of 1% HAuCl4, and 
800 ml H2O. Various seed particle volumes (200-500 µl) were added to 1 ml of the plating 
solution. 10 µl of formaldehyde (HCHO, 37%) was added to the solution with rapid mixing. 
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This causes a reduction reaction in which the absorbed colloids of the seed particles serve as 
nucleation sites for shell growth by additional reduced gold ions. Formulations that produced 
particles with an extinction profile peak near 800 nm were linearly scaled up. After synthesis, 
nanoshells were washed by one round of centrifugation (1500xg, 10 min) and resuspended in 
1.81 mM K2CO3 for storage. Before use in subsequent applications, stored nanoshells were 
washed via one centrifugation round (1500xg, 10 min) and resuspended in H2O.  
As synthesized, these particles were found to have a diameter of 153.65 (±8.96) nm. 
A TEM image of synthesized gold-silica nanoshells and their extinction spectra is shown in 
Figure 3.2 below. 
 
Figure 3.2.  Gold-silica nanoshell characterization. [A] TEM image of synthesized gold-silica 
nanoshells. [B] Extinction spectra of synthesized gold-silica nanoshells. Particles were synthesized to 
have maximum light absorption in the NIR region.  !
3.3 POLY(NIPAAM-CO-AAM) HYDROGEL  SYNTHESIS !
Poly(NIPAAm-co-AAm) hydrogels were synthesized using free radical 
polymerization. Prior to synthesis, NIPAAm (Aldrich, 97%) was dissolved in tetrahydrofuran 
(THF) and recrystallized in n-hexane. This step removes the small molecule inhibitor p-
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methoxyphenol from the packaged NIPAAm. The recrystallization process was repeated at 
least 3 times and the final product was dried by lyophilization and stored at -20oC. Stock 
solutions of NIPAAm (1.75 M), AAm (Sigma, ≥99%, 15 M), and N,N’-
methylenebisacrylamide (MBAAm) (Sigma, ≥98%,  0.169 M) were made in water. A 
prepolymer solution of a 95:5 molar ratio of NIPAAm:AAm and a 1:750 molar ratio of 
monomer:crosslinker (MBAAm) was created from the stock solutions: 3.56 ml 1.75 M 
NIPAAm, 21.88 µl 15 M AAm, and 51.78 µl 0.169 M MBAAm and 116.34 µl H2O were 
added to a three-neck round bottom flask (3.75 ml total). Argon (Ar) gas was bubbled 
through this solution for at least 15 min in order to remove dissolved O2, which inhibits the 
polymerization process. With rapid stirring, 37.5 µl of 10% (w/v) ammonium persulfate 
(APS, Sigma-Aldrich, ≥98%) and 7.5 µl of N,N,N′,N′-tetramethylethylenediamine (TEMED, 
Sigma, ≥99%) were added to initiate the redox reaction for free radical polymerization. 
Composite hydrogels were synthesized in a similar fashion, with 8x109 nanoshells/ml being 
added to the prepolymer solution prior to adding APS/TEMED. The polymerization solution 
was then quickly poured into a mold consisting of 2 glass slides separated by a 1.5 mm 
Teflon® spacer held together by metal clamps. The hydrogel was then cured at 30oC for 2 h 
under vacuum. After curing, the hydrogel slab was soaked in 95% EtOH for at least 12 h 
followed by H2O for at least 12 h to remove any organic solvents and unreacted monomers. 
Hydrogel disks of a 4 mm diameter were punched out with a cork borer. A schematic of this 
polymerization process is shown in Figure 3.3 below. 
! 44 
 
Figure 3.3. Poly(NIPAAm-co-AAm) hydrogel synthesis. A solution of a 95:5 molar ratio of the 
monomers NIPAAm:AAm and a 1:750 ratio of crosslinker MBAAm:monmers is polymerized by free 
radical polymerization initiated by APS and TEMED. !
3.4 THERMAL ANALYSIS OF HYDROGEL-NANOSHELL COMPOSITES !
After synthesis, the swelling behavior of the poly(NIPAAm-co-AAm) gels was 
analyzed in response to temperature. The hydrogels were allowed to swell at room 
temperature (22oC) for at least 24 h before testing. To determine the LCST of the hydrogels, 
the gels were first weighed and placed in TRIS buffer (pH 7.4) and then incubated at various 
temperatures (29oC, 33oC, 37oC, 41oC, 45oC, and 50oC) for 10 min. After incubation, the gels 
were weighed again, and the deswelling of the gel was calculated using Equation 3.1 below. 
!"#$"%%&'(! "#$%! % = !!"" ∗ ! !"#$%&!"#$!"#$%&!"#$!!!!!                  Equation 3.1 
 
Results, illustrated in Figure 3.4, show that these gels tend to collapse from 39-45oC, a 
temperature range slightly above physiologic temperature.  
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 Next, the thermal behaviors of hydrogels with and without nanoshells were compared. 
These gels were either incubated in 2 ml TRIS buffer (pH 7.4) in a 50oC water bath or 
exposed to an NIR laser (Coherent Diode, 808 nm, 8 W/cm2, 30 min). Gels were weighed 
every 10 min for 30 min and the deswelling of the gel was calculated using Equation 3.2. 
!"#$"%%&'(! "#$%! % = !!"" ∗ !"#$%&!!"#$%&!!!               Equation 3.2 
 
Results are shown in Figure 3.5. Both gels with and without nanoshells displayed 
similar behavior when incubated at 50oC, indicating that the presence of nanoshells did not 
inhibit hydrogel collapse. When exposed to the NIR laser, gels with nanoshells deswelled 
similarly to the gels incubated at 50oC, while gels without nanoshells exhibited minimal 
deswelling in response to the laser. This demonstrated that both the presence of nanoshells 
Figure 3.4. LCST of poly(NIPAAm-co-AAm) hydrogels. Deswelling of NIPAAm-co-AAm 
hydrogels as a function of temperature. These hydrogels collapse between 39-45oC. Deswelling ratio 
was calculated using Equation 3.1. 
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and exposure to an NIR laser were required to cause gel deswelling when heating with NIR 
light.   
 
Figure 3.5. Deswelling in response to temperature changes and irradiation. Deswelling of 
NIPAAm-co-AAm hydrogels with and without nanoshells by either incubation in a 50oC water bath 
or exposure to an NIR laser. Deswelling ratio calculated using Equation 3.2. 
3.5 CONCLUSIONS 
 
 In this chapter, a poly(NIPAAm-co-AAm)-gold nanoshell composite material was 
synthesized. This material has an LCST of around 39-45oC, meaning it will be swollen at 
physiologic temperature. Expulsion of absorbed water and collapse of the material was found 
to follow both incubation at 50oC and exposure to a NIR laser. With these results, we moved 
forward to use this optically induced phase transition to trigger drug release from the material, 
as described in Chapter 4. 
!
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4 THERAPEUTIC DELIVERY FROM HYDROGEL-NANOSHELL 
COMPOSITES  
 
After analysis of the thermal deswelling of the bulk poly(NIPAAm-co-AAm) 
hydrogels, delivery studies of two different cancer therapeutics were performed: the 
chemotherapeutic doxorubicin (dox) and ssDNA as a model molecule for siRNA. A 
comparison of the two therapeutics is found in Table 4.1 below. 
4.1 DESCRIPTION OF THERAPEUTICS 
 
!
Figure 4.1. Chemical structure of doxorubicin. !
Doxorubicin is a small molecule (580 Da) chemotherapeutic indicated in a wide 
variety of cancers including hematopoietic malignancies; carcinomas of the breast, lung, 
ovary, stomach, and thyroid; and sarcomas of bone and soft tissue7. The chemical structure of 
doxorubicin can be seen in Figure 4.1. Its optical properties allow for observation via both 
absorbance and fluorescence103. Doxorubicin, first known as an anthracycline antibiotic, was 
discovered to have anti-tumor effects in the 1960s104. The primary mechanism of action is 
intercalation with DNA during replication, causing inhibition of topoisomerase II binding 
and arrest of cell replication105. Side effects of doxorubicin include myelosuppression, 
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mucositis, and cardiac toxicity; furthermore, these side effects often cause patients to cease 
doxorubicin therapy, even if the drug is still effective against their malignancy1.  
The second therapeutic analyzed was single-stranded DNA (ssDNA), used as a model 
molecule for siRNA. Typical siRNAs are double-stranded with sticky ends and have a 
molecular weight of 13-15 kDa. Details regarding the mechanism of action of siRNAs can be 
found in Section 1.3.1. This study employed a 21 base pair oligonucleotide equivalent in 
sequence to the siRNA used to target the EphA2 protein. EphA2 is a receptor tyrosine kinase 
known to be upregulated in many cancers, Its functions include signaling involved in cell-cell 
contacts, cell migration, and angiogenesis106. Down regulation of EphA2 has been shown to 
reduce tumorigenecity in preclinical studies of several cancer types, including pancreatic and 
breast carcinomas107.  
 
Table 4.1. Comparison of Doxorubicin and siRNA. 
 Doxorubicin siRNA 
Drug type Chemical Biologic 
Size 580 Da 13-15 kDa 
Chemical Properties Hydrophobic Hydrophillic 
Intracellular Transport Passive diffusion Endosomal 
Mechanism of Action Inhibition of topoisomerase 
II 
Prevents translation of 
complimentary mRNA 
sequences 
Benefits for controlled 
delivery 
Minimize off-site toxicity Increase serum stability  
Detection methods  Absorbance (485 nm) or 
fluorescence (585 nm) 
Absorbance at 260 nm  
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4.2 THERAPEUTIC RELEASE FROM COMPOSITES 
 
First, hydrogels with and without nanoshells were dried under vacuum for at least 48 
h prior to drug loading. The dry weights of the gels were recorded. For the doxorubicin trials, 
the gels were then soaked in a 0.5 mg/ml (862 mM) solution of doxorubicin (Sigma) in TRIS 
buffer (pH 7.4) at 4oC for at least 24 h. Absorbance readings of loaded gels were used to 
determine the loaded concentration of doxorubicin. For the dsDNA trials, the gels were 
soaked in a 25 mM solution of ssDNA (Invitrogen) in DNase free H2O at 4oC for at least 24 
h. The concentration of ssDNA in the loaded gels was determined by measuring the ssDNA 
concentration of the soak solution before and after gel soaking.  
Loaded gels were placed in TRIS buffer (doxorubicin gels) or DNAse free H2O 
(ssDNA gels) and then either incubated at 50oC for 30 min in a water bath or exposed to an 
NIR laser (Coherent Diode, 808 nm, 8 W/cm2, 30 min). In addition, control gels with 
nanoshells were kept at room temperature (22oC) for 30 min. Every 5 min, a buffer sample 
was analyzed for drug content. To determine doxorubicin concentration, absorbance at 485 
nm was used to extrapolate a concentration value based on a standard curve (R2 = 0.99968). 
DNA concentration was determined by absorbance at 260 nm using a Nanodrop® 
spectrophotometer.  
Release of both doxorubicin and dsDNA from poly(NIPAAM-co-AAm) gels was 
then analyzed. Figure 4.2 shows release from gels in response to incubation at 50oC, and 
Figure 4.2 shows release from gels in response to an NIR laser. Gels incubated at 50oC with 
and without nanoshells showed similar release profiles, indicating that the presence of 
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nanoshells did not affect drug release. Approximately 77% of the loaded doxorubicin and 
85% of the loaded ssDNA were released within 30 minutes.  
 
Figure 4.2. Drug release due to incubation. Drug release from poly (NIPAAm-co-AAm) hydrogels 
with and without nanoshells in response to incubation at 50oC. 
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Figure 4.3. Drug release in response to NIR irradiation.  Irradiated gels with nanoshells provide 
increased drug delivery over controls at all times t>0 (p<0.05). 
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Doxorubicin and ssDNA delivery after NIR irradiation indicated that nanoshell-
composites provide increased drug release over controls for all times t>0, as analyzed by a 
two-sided t-test with a 95% confidence interval. Results from this study indicated that 
delivery of cancer therapeutics from a poly(NIPAAm-co-AAm) –nanoshell composites could 
be triggered by exposure to NIR light. 
4.2.1 Delivery of double-stranded DNA (dsDNA)  !
 In addition to initial validation of siRNA delivery using a ssDNA oligo, further tests 
were completed using double-stranded DNA (dsDNA) instead of ssDNA, as this is more 
similar to siRNA, which is also double stranded. Two properties of dsDNA are important to 
consider when using this delivery platform. First, ssDNA oligos are significantly more 
flexible than dsDNA oligos since they do not form a helix108,109. Second, dsDNA oligos are 
more thermally-sensitive, as the two strands are held together by supramolecular interactions 
such as hydrogen bonding, whereas the bonds between bases in ssDNA are predominantly 
covalent. For this study, a 21 base pair dsDNA oligo was loaded into gels, and release was 
measured in response to NIR irradiation. In addition, delivered DNA oligo integrity was 
assayed using poly(acrylamide) gel electrophoresis (PAGE).  
Therapeutic loading into the gels was performed similarly to methods described in 
Section 3.2. Gels were soaked in a 17 mM solution of dsDNA (Integrated DNA Technologies, 
inc.) in duplex buffer (Integrated DNA Technologies, inc.) at 4oC for at least 24 h. Loaded 
gels were placed in duplex buffer gels and then either exposed to an NIR laser (Coherent 
Diode, 808 nm, 8 W/cm2, 30 min) or left at room temperature for 30 min. Every 5 min, a 
buffer sample was analyzed for drug content. DNA concentration was determined by 
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absorbance at 260 nm using a Nanodrop® spectrophotometer. Results are shown in Figures 
4.4 and 4.5.  
!
Figure 4.4. Delivery of [A] doxorubicin and [B] dsDNA in response to NIR irradiation. (*p<0.05, 
**p<0.01 as compared to laser no nanoshells).  
Results from Figure 4.4 indicated that delivery of both chemical and biological cancer 
therapeutics, such as doxorubicin and dsDNA, can be triggered by exposure to NIR light. A 
closer look at ssDNA vs dsDNA delivery from these composites is shown in Figure 4.5.  
!
Figure 4.5. Delivery of [A] dsDNA vs [B] ssDNA in response to NIR irradiation. (p<0.01, as 
compared to room temp + nanoshells).  
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These results show that overall, a higher molar concentration of ssDNA can be delivered 
from the composites compared to dsDNA, most likely due to the decreased size and 
increased flexibility of the ssDNA oligo compared to the dsDNA oligo. In addition, for both  
control groups, less dsDNA was delivered compared to ssDNA, as the increased size and 
stiffness of the dsDNA oligo also inhibited passive diffusion of the therapeutic out of the gel.  
 To ensure that the heating of the gel during the material transition did not denature 
the dsDNA oligo, the delivered product was run on a native poly(acrylamide) gel. A 20% 
poly(acrylamide) gel was synthesized by mixing a 19:1 molar ratio of AAm:MBAAm in tris-
acetate-EDTA (TAE) buffer. The gel had a volume of ~20 ml and was polymerized by the 
addition of 300 µl 10% APS (w/v in H2O) and 30 µl TEMED.  The gel was loaded with a 10 
bp ladder, the annealed dsDNA oligo as a positive control, and dsDNA oligo obtained from 
irradiating a loaded composite gel at for 30 min (808 nm, 8 W/cm2). The gel was run at 120 
V for 3 h and then stained with both SYBR gold (Invitrogen) and SYBR green (Invitrogen) 
by incubation of the gel with the appropriate stain for 15 min. SYBR gold stains all DNA 
content, while SYBR green preferentially stains dsDNA. The gel was then imaged under UV 
fluorescence, with the results shown in Figure 4.6.   
! 54 
!
Figure 4.6. PAGE of delivered DNA. Gel electrophoresis of [1] 10 bp ladder, [2] annealed dsDNA 
oligo, and [3] dsDNA oligo delivered via NIR irradiation. 
 
Results from Figure 4.6 showed that the delivered dsDNA oligo ran as a single band at 21 bp, 
the same size as the annealed dsDNA control. There were no bands present below the band at 
21 bp, which would have indicated the presence of lower MW ssDNA. This suggests the 
delivered dsDNA oligo was in its double-stranded form.  
4.3 CONCLUSIONS 
 
These results validate the hypothesis that cancer therapeutics can be triggered to 
release from poly(NIPAAm-co-AAm)-gold nanoshell composites in response to NIR 
irradiation. This suggests that this material is promising for use in a remote-controlled drug 
delivery platform. However, for such a platform to have a strong clinical impact it must be 
able to be administered non-invasively. To achieve this, these composites could be 
synthesized as nano-scale sized particles, such that they can be injected intravenously. 
Chapter 5 of this thesis describes how such particles can be synthesized.  
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5 NANOSCALE HYDROGEL-NANOSHELL COMPOSITE SYNTHESIS 
AND CHARACTERIZATION !
5.1 5.1 INTRODUCTION !
In the previous two chapters of this thesis, a composite material for optically triggered 
drug delivery was synthesized and validated. The next goal is to synthesize this material as 
particles which are < 1 micron. These particles will be of a similar size to the nanoshells used 
in the studies discussed in Section 2.2.3; therefore the particles can be injected intravenously 
and will passively accumulate in tumor tissue due to the EPR effect. Once the particles reach 
the tumor site, an NIR laser will be applied to the tumor. As previously described, this will 
cause a rapid heating of the embedded nanoshells, which in turn triggers a collapse of the 
polymer coating and release of absorbed drug molecule directly at the tumor site. Figure 5.1 
below illustrates this process. 
!
Figure 5.1. Schematic of hydrogel-nanoshell composite particle therapy. (1) Injected particles 
will circulate and passively accumulate into tumor tissue. (2) An applied NIR laser causes rapid 
heating of the embedded nanoshells. (3) The resulting temperature increase causes release of 
absorbed drug molecules from the thermally responsive coating directly at the tumor site.  
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5.2 TECHNIQUES FOR SYNTHESIS OF NANOSCALE HYDROGEL PARTICLES !
 In recent years, several methods have been developed to synthesize nanoscale 
polymer particles. Many of these methods are based on soft lithography techniques110. Soft 
lithography is generally characterized by the creation of an elastomeric stamp or mold using 
microfabrication techniques developed in the electronics industry110. Two such techniques 
include Particle Replication In Nonwetting Templates (PRINT)111 and the hydrogel template 
method112. 
5.2.1 PRINT !
The PRINT method developed by the DeSimone group uses photocurable 
perfluoropolyether (PFPE) molds to emboss a prepolymer solution onto a highly fluorinated 
surface111. Such surfaces are nonwetting to organic materials, thereby preventing the 
background “scum” layer commonly seen with traditional imprint lithography (Figure 5.2)111.  
!
Figure 5.2. PRINT compared to traditional imprint lithography. In traditional imprint lithography, 
the affinity of the liquid precursor to the surface of the substrate results in a scum layer. In PRINT, 
the non-wetting surface causes the liquid precursor to be confined only in the wells of the mold, 
resulting in the synthesis of isolated particles. From Rolland et al. 2005111. 
chemical structure that would be necessary to fabricate and
harvest organic particles.
Here, we report a very general technique, Particle Replication
In Nonwetting Templates (PRINT), for the fabrication of
monodisperse particles with simultaneous control over structure
(i.e., shape, size, composition) and function (i.e., cargo, surface
structure). To demonstrate the utility and generality of PRINT
for particle generation, we have fabricated monodisperse,
multifunctional particles from technologically relevant materials,
including poly(ethylene glycol), poly(D-lactic acid), poly-
(pyrrole), and a triacrylate resin, with sizes below 200 nm and
with precise shape control. The compatibility of PRINT with
fragile biological cargos and recognition agents is demonstrated
by incorporating DNA, proteins, and small-molecule therapeu-
tics into sub-200 nm poly(ethylene glycol) nanoparticles using
a simple and general encapsulation technique. The ability to
independently control particle characteristics, such as size, shape,
composition, cargo, and surface structure, makes PRINT
uniquely suited to fabricate particles for many applications.
PRINT addresses many of the fundamental shortcomings of
other particle fabrication methods. It enables the top-down
fabrication to below 100 nm dimensions with orthogonal control
of size, shape, and composition by taking advantage of
significant advances in “soft lithographic” molding technology
that were developed to achieve this goal. This scalable method
to generate and harvest nanoparticles enables the possibility of
a “particle foundry”sthe functional equivalent of the continuous
fabrication methodologies employed by the microelectronics
industrysfor fabricating delicate organic particles necessary for
use in nanomedicine and other emerging nanotechnologies.
Here, we have used photocurable perfluoropolyether (PFPE)
molds to emboss liquid precursor compounds using highly
fluorinated surfaces that are nonwetting to organic materials,
which enables the fabrication of isolated objects with superior
shape and composition control but without harsh processing
steps (Figure 1). We have previously demonstrated that these
PFPE molds have superior replication properties for use in
lithographic applications in the microelectronics industry,
including sub-50 nm lateral resolution, clean surface release,
and precise control over replication morphology.22 Unlike other
materials, such as poly(dimethylsiloxane) (PDMS), PFPE-based
molds are both nonwetting and nonswelling to both inorganic
and organic materials.23 Though PRINT is akin to other soft
lithographic molding methods, it is unique because it produces
isolated particles instead of embossed films. This is especially
important as one gets to nanometer size ranges because the
dimensions of the desired objects approach the dimensions of
the residual film, typically called a “scum layer” or “flash
layer”.16-19 Other soft lithographic molding techniques typically
produce scum layers because the material to be molded has
(22) Rolland, J. P.; Hagberg, E. C.; Denison, G. M.; Carter, K. R.; DeSimone,
J. M. Angew. Chem., Int. Ed. 2004, 43, 5796-5799.
(23) Rolland, J. P.; Van Dam, R. M.; Schorzman, D. A.; Quake, S. R.; DeSimone,
J. M. J. Am. Chem. Soc. 2004, 126, 8349-8349.
Figure 1. Illustration of the PRINT process compared to traditional imprint lithography in which the affinity of the liquid precursor for the surface results
in a scum layer. In PRINT, the nonwetting nature of fluorinated materials and surfaces (shown in green) confines the liquid precursor inside the features of
the mold, allowing for the generation of isolated particles.
Fabrication and Harvesting of Nanobiomaterials A R T I C L E S
J. AM. CHEM. SOC. 9 VOL. 127, NO. 28, 2005 10097
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This method has been used to synthesize various different particles made of materials such as 
poly(D-lactic acid), PEG hydrogels, and proteins; from sizes ranging from 80 nm to 20 
µm111,113. Particles have been synthesized to be pH sensitive114,115, and have been loaded with 
chemotherapeutics114 and contrast agents116,117.  
5.2.2 Hydrogel Template Method 
A novel method for synthesizing homogenous polymer particles was recently 
reported by the Park group112,118. This method relies on the use of a hydrogel template made 
of a material such as gelatin112. These gelatin templates can be easily made through common 
microfabrication techniques. They are mechanically stable enough to act as a mold yet 
undergo a sol-gel transition upon heating112. This process can be used to make polymer 
particles from 200 nm to larger than 50 µm. The hydrogel template process is summarized in 
Figure 5.3.  
!
Figure 5.3. The hydrogel template method for particle synthesis. [A] A silicone wafer master is 
created with vertical posts of desired particle size. [B] A warm aqueous gelatin solution is poured on 
top of the master. [C} The gelatin is cooled to solidify and peeled off the master to expose cavities. 
[D] Cavities are filled with polymer mixture and dried to remove organic solvent. [E] Mold is 
dissolved in warm H2O, and particles are collected by centrifugation or filtration. From Acharya et al. 
2010112.  
Author's personal copy
in large quantities in a reproducible manner by simple microfabrication
processing steps. Thus, it is desirable to develop a method that can
collect formed particles by simply dissolving the templates in aqueous
solutions. It would be even more desirable if the drug-containing
particles can be delivered while they are still in the templates. For this
reason, a hydrogel systemthat canbe fully dissolved in aqueous solution
was contemplated. It was not clear, however, whether this approach
would be feasible, because it is well known that hydrogels, especially
sol–gel phase reversible hydrogels, do not have a mechanical strength
high enough tobeused as templates, and the condition for sol–gel phase
transition can be too harsh for loaded drugs. It was unexpectedly found,
however, that gelatin could be manipulated to possess a mechanical
strength sufﬁciently high enough for use as templates with a gel-to-sol
transition temperature low enough not to adversely affect the loaded
drugs.
Fig. 1 shows the main idea of the hydrogel template approach. The
ﬁrst step is to form a pattern of vertical posts on a silicon wafer master
template (Fig. 1A). If an intermediary silicone rubber template is to
be used, then the vertical posts on the master template will become
vertical cavities. On top of the master template is poured a warm
aqueous gelatin solution, and then the temperature is lowered to
form a gelatin hydrogel imprint (Fig. 1B). Once the gelatin layer is
solidiﬁed, the gelatin mold is peeled off and the gelatin mold is
placed on the ﬂat surface to expose the cavities (Fig. 1C). The cavities
in the gelatin mold are ﬁlled with a solution or a paste of drug/
polymermixture (Fig. 1D). In this study, poly(lactic-co-glycolic acid)
(PLGA) was used as a model biodegradable polymer, and Nile Red, a
ﬂuorescent probe, was used for easy visualization unless speciﬁed
otherwise. The organic solvent present inside the cavities is removed
by drying, and the formed particles are collected by simply
dissolving the hydrogel mold, followed by centrifugation or ﬁltration
(Fig. 1E).
3. Materials and methods
3.1. Materials
Gelatin (from porcine skin, Type A, 300 bloom), 1,6-diphenyl-
1,3,5-hexatriene (DPH), 6-propionyl-2-dimethylaminonaphthalene
(Prodan), and Nile Red were purchased from Sigma (St. Louis, MO,
USA), and poly(lactic-co-glycolic acid) (PLGA) of different molecular
weights (MW 36,000, IV 0.7 dL/g; MW 65,000, IV 0.82 dL/g; MW
112,000, IV 1.3 dL/g) were purchased from Lactel (Pelham, AL).
3.2. Fabrication of a silicon wafer master template by photolithography
A silicon wafer was spin coated with SU8 2010 photoresist
(Microchem, MA) at 3500 rpm for 30 s followed by baking at 95 °C
for 3 min. The photoresist coated silicon wafer was exposed to UV
radiation through a mask containing a 10 µm diameter circular
pattern for 12 s. Please note that the diameter can be changed to any
other value of interest, and any speciﬁc sizes used in this article are
just for a demonstration purpose. After exposure, the silicon wafer
was post baked at 95 °C for 3 min followed by development in SU-
8 developer for 2 min. The silicon wafer was rinsed with isopropanol
and dried with nitrogen gas. The wafer thus fabricated contained
10 µm diameter wells.
3.3. Fabrication of silicon master templates by electron beam (e-beam)
lithography
Making surface patterns of submicron sizes requires e-beam
lithography. Circular patterns of 500 nm squares were designed using
theAutoCAD2007program. A3-in. diameter siliconwafer coveredwith
1 µm thick SiO2 layer (University Wafer, South Boston, MA) was spin
coated with poly(methyl methacrylate) (PMMA, Microchem, Newton,
MA) photoresist of 300 nm thick layer using a spin coated at 3500 rpm
for 30 s (SCS P6708 spin coating system, Indianapolis, IN). The coated
PMMA photoresist layer was exposed to e-beam in a preprogrammed
pattern using a Leica VB6 High Resolution Ultrawide ﬁeld e-beam
lithography Instrument (Bannockburn, IL) operating at 100 KV,
transmission rate 25 MHz current 5 nA. After e-beam lithography, the
silicon wafer was developed in 3:1 isopropanol:methyl isobutyl ketone
solution to remove exposed regions of the photoresist. A 5 nm thick
chromium layer and a 20 nm thick gold layer were successively
deposited on to this pattern followed by liftoff of the residual PMMA
ﬁlm in reﬂuxing acetone. The pattern was transferred to the underlying
silicon oxide by deep reactive ion etching with SF6/O2 plasma. The
generated silicon master template was used in the fabrication of
hydrogel templates.
3.4. Fabrication of hydrogel templates
A clear gelatin solution (30% w/v in aqueous solution, 10 ml) at
50–55 °C was transferred with a pipette onto a silicon master
template (3in. diameter) containing circular pillars (e.g., of 10 μm
diameter and 10 μmheight). The gelatin solutionwas evenly spread to
form a thin ﬁlm completely covering the master template and cooled
to 4 °C for 5 min by keeping it in a refrigerator. Cooling resulted in
formation of a gelatin template which was subsequently peeled away
from the master template. The obtained gelatin template was ∼3in. in
diameter, and contained circular wells (e.g., of 10 μm diameter and
10 μmdepth). The gelatin template was examined under a bright ﬁeld
reﬂectance microscope to determine its structural integrity. The
preliminary experiment suggested that a solution of 30% gelatin
resulted in templates which were elastic and mechanically strong
enough for further processing.
3.5. Polymeric microstructures
200 μl of 40% PLGA solution (MW112,000, IV 1.3 dL/g)w/v in CH2Cl2
doped with Nile Red was transferred with a pipette onto a gelatin
template containing circular trenches of, e.g., 10 μmdiameter anddepth.
The PLGA solution was evenly spread. The PLGA-ﬁlled gelatin template
was left to dry at room temperature (∼25 °C) for 5–10 min. The gelatin
template ﬁlledwith PLGA solutionwas characterized by bright ﬁeld and
ﬂuorescence microscopy.
3.6. Collection of free microstructures
Gelatin templates ﬁlled with PLGA solution were left at room
temperature for 10 min to remove most of CH2Cl2 solvent from the
templates. For complete removal of the solvent, extended drying at
elevated temperatures or freezedrying canbeused. Abatchof 10gelatin
templates were dissolved in a 100 ml beaker containing 50 ml of
Nanopure water at 40 °C and gently shaken for 2 min to completely
dissolve the templates. This step resulted in complete release of the
free and isolated microstructures into the solution. The dispersion
was transferred into conical tubes (15 ml) and centrifuged for 5 min
(Eppendorf Centrifuge 5804, Rotor A-4-44, at 5000 rpm, 19.1 RCF,
Fig. 1. Schematic description of the hydrogel template approach for fabrication of
homogeneous microstructures. See text for descriptions of steps A–E.
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An initial study examined the versatility of the synthesis method by fabricating 
poly(lactic-co-glycolic)acid (PLGA) particles of various sizes (from 200 nm up to 50 µm) 
and of various shapes, as shown in Figure 5.4112.  
!
Figure 5.4. Various shapes of particles synthesized from the hydrogel template method. Particle 
size is 50 µm. From Acharya et al. 2010112. 
A further study by Acharya et al. analyzed drug release from degrading PLGA 
microparticles118. These particles displayed extremely high drug loading capabilities (>50% 
wdrug/wPLGA) and delivered ~80-100% of loaded drug within 20-25 days. Release kinetics 
were dependent on surface area, diffusion coefficient, and concentration gradient118. 
5.3 HYDROGEL-NANOSHELL COMPOSITE PARTICLE SYNTHESIS !
The hydrogel template method described in Section 4.2.2 was used to synthesize 500 
nm poly(NIPAAm-co-AAm) hydrogels with embedded nanoshells.  First, a silicone wafer 
master with 500 nm cylindrical (i.e., 500 nm in diameter and 500 nm in height) vertical posts 
was created using photolithography. Each 2-inch square template contained 5x108 posts. 
Next, 4 ml of a warmed (50-55 oC) 20% w/v aqueous Gelatin Type A (Sigma) solution was 
poured over the silicone master. After allowing the gelatin to solidify by incubating at 4oC 
Author's personal copy
structures on their biological behavior, such as blood circulation times,
targeting, and cellular internalization for intravenous administration of
submicron sizes [16,17]. But the effect of the shape on biological
response has not been fully examined, mainly due to the lack of
availability of suchparticulate systems. Traditional emulsionmethodsof
preparing nano/microparticles result in spherical shape, and only
recently, formation of particles in a variety of different geometries
became possible as a result of advances in nano/microfabrication
techniques. Microstructures with complex geometries inﬂuence the
anisotropic interactions with biomolecules through steric or spatially
segregated surface functionalities. Phagocytosis by macrophages and
the renal and hepatic clearance of microstructures are also known to be
inﬂuenced by the geometry of nano/microstructures [18].
It will be useful to generate a comprehensive library of micro-
structures with complex geometries to examine their potential beneﬁts
of targeted drug delivery. Figs. 2 and 3 show formation of disc shape
particles, and Figs. 4 and 5 show the capability of making micro-
structures with almost any geometry. Furthermore, the hydrogel
template approach can also be used to prepare multi(n)-layered
microstructures by simply ﬁlling the cavities of the template n times.
Thus, the same drug can be loaded at different concentrations or
different drugs canbe loaded into the sameparticles. Suchmulti-layered
structures are useful in makin ven more advanced structures, e.g.,
capsules, for delivery of fragile drugs, such as peptide and protein drugs,
and in making multi-functional systems. The ease and ﬂexibility of the
hydrogel template approach are expected to ﬁnd applications in
delivery of diverse drugs, ranging from low molecular weight
hydrophobic drugs to high molecular weight proteins. The hydrogel
template approach provides a newoption of fabricatingmicrostructures
with various geometries and with multi-functional systems.
6. Conclusions
A hydrogel template approach was developed to prepare homo-
geneous nano/micro structures of various geometries. This can be
readily applicable for the large scale production of nano/microparti-
cles because of its easiness in producing particles. The ﬂexibility in
forming different microstructures allows the approach to incorporate
diverse drugs ith various hydrophilic characters and molecular
weights. The study demonstrated production of particles in various
geometries and sizes with high precision. Drug loading is also shown to
be very high with controllable drug release kine ics. The hydrogel
template approach provides a new avenue of preparing nano/micro-
particles for drug delivery.
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for 15 min, it was peeled from the master, revealing a template with circular wells of 500 nm 
diameter and 500 nm height.  
After template synthesis, a prepolymer solution containing NIPAAm, AAm, and 
MBAAm in H2O was made as described in Section 2.2 (95:5 ratio of NIPAAm:AAm, 1:750 
ratio of MBAAm:monomers). In addition, gold-silica nanoshells were added to this solution 
at a concentration of 1.5x1010 particles/ml. Aliquots of 100 µl were made of this prepolymer 
suspension, and polymerization was then initiated by addition of 2.5 µl APS (10% w/v in 
H2O) and 0.5 µl TEMED. After rapid mixing by vortexing, 50 µl of this solution was pipetted 
onto a gelatin template and whisked across using a razor blade at a 45o angle to completely 
fill the template wells. At the nanoshell concentration used, it was estimated that 1.5 
nanoshells would be loaded in each well of the template. The particles were polymerized for 
2 h at room temperature. 
After polymerization, each template was dissolved in 10 ml H2O (with 0.1% w/v 
NaN3 to prevent microbial contamination) and incubated at 50-55oC for 30-60 min. The 
hydrogel-nanoshell composite particles (HNCPs) were then purified by 2 rounds of 
centrifugation (2000xg, 5 min) and ran through a 5 µm filter. Poly(NIPAAm-co-AAm) 
hydrogel particles without nanoshells (NHPs) were synthesized analogously without adding 
nanoshells to the prepolymer solution. A schematic of this process is shown below.  
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Figure 5.5. Particle synthesis based on hydrogel template method. [1] Master created with 
cylindrical posts 500 nm (diameter) by 500 nm (height). [2] Warm gelatin poured over master. [3] 
Cooled gelatin peeled off of master to reveal cavities 500 nm (diameter) by 500 nm (height). [4] 
Prepolymer solution and gold-silica nanoshells poured into cavities. Polymerization is initiated by 
APS/TEMED. [5] After polymerization, gelatin template is dissolved in warm water and HNCPs are 
collected by centrifugation.  !
5.4 IMAGING ANALYSIS !
After synthesis, HNCPs were characterized using a JEOL 1230 High Contrast TEM 
for visual inspection of the poly(NIPAAm-co-AAm) polymer as well as any embedded gold 
nanoshells. Figure 5.6 shows a comparison, with the HNCPs having a thin polymer coating 
around the gold nanoshells. Since samples must be fully dehydrated before imaging, this 
coating is much smaller than it would be in its hydrated state. In addition, this drying process 
also provides a driving force for HNCPs to aggregate, causing many of the particles to be 
seen as multiple particle aggregates instead of individual particles.  
[1]$ [2]$
[3]$ [4]$ [5]$
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Figure 5.6. Analysis of HNCPs by TEM. [A-C] TEM images of HNCPs compared to [D-F] TEM 
images of bare nanoshells.  !
5.5 THERMAL ANALYSIS VIA DYNAMIC LIGHT SCATTERING !
Dynamic light scattering (DLS) measures the Brownian motion of particles in a liquid 
to extrapolate their hydrodynamic radius119. Both HNCPs and NHPs were sized using a 
Brookhaven 90-Plus Particle Size Analyzer under three different conditions: at 25oC, at 50oC, 
and after being exposed to NIR irradiation (808 nm, 5 W/cm2, 5 min). While this provides a 
technique to determine the size of sub-micron particles in a hydrated state, measurements are 
dependent on many factors, including the material refractive index119. For the NHPs, the 
refractive index of poly(NIPAAm) was used (1.52)120. However, HNCPs consist of two 
different materials with drastically different refractive indices. For these measurements, the 
refractive index of gold was used (0.169 + 3.821i). In addition, DLS measurements assume 
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particles are spherical, whereas these particles are cylindrical119. Due to these limitations, the 
hydrodynamic diameters measured are most likely not the particle’s true size, so 
measurements for each particle type are normalized to its measurement at 25oC. The results 
of this study are summarized in Figure 5.7. NHPs have a significantly smaller diameter when 
incubated at 50oC, while the HNCPS have a significantly smaller diameter when either 
incubated at 50oC or exposed to NIR irradiation (as determined Student’s t-test, n=3). 
!
Figure 5.7. Analysis of HNCP thermal deswelling. Hydrodynamic diameters of hydrogel-only and 
hydrogel-nanoshell composite particles as measured by DLS. Measurements are normalized to 
particle size at 25oC. Hydrogel-only particles deswell in response to increased temperature, while 
hydrogel-nanoshell particles deswell in response to either increased temperature or exposure to NIR 
irradiation. (*p<0.05, **p<0.01).  !
Additionally, when particles were measured in their collapsed state, two separate size 
populations emerged, as displayed in Figure 5.8. A population at a smaller diameter 
represented single particles, while a second population centered around a larger diameter 
likely resulted from the aggregation of multiple particles.  The material phase transition that 
causes polymer collapse will also act as a driving force for aggregation due to the 
hydrophobic effect. For the data displayed in Figure 5.7, only the “single particle population” 
of these measurements was used.  
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Figure 5.8. Typical size distribution of HNCPs in their collapsed stage after irradiation. The 
particles exhibited two distinct populations, hypothesized to be single particles vs. particle aggregates.   !
5.6 CONCLUSIONS !
The composite material described in Chapters 3-4 was synthesized as nanoscale 
particles by using a dissolvable gelatin template. Image analysis using TEM indicates that the 
resulting particles consist of a nanoshell core surrounded by thin polymer layer. The 
hydrodynamic diameter of these particles decreases in response to either incubation at 50oC 
or exposure to NIR irradiation, proving that these particles retain the same thermal properties 
as the bulk material. This indicates the potential of this material to be used as an injectable-
sized platform for therapeutic delivery.  
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6 CONCLUSIONS AND FUTURE DIRECTIONS 
 
This thesis presents work towards the creation of a novel controlled drug delivery 
system for cancer therapeutics. Unlike delivery systems already on the market, this platform 
would be administered non-invasively and allow delivery only at the site of malignant cells. 
Herein, the results and significance of this work will be discussed.  
6.1 DEVELOPING AN OPTICALLY-TRIGGERED DELIVERY SYSTEM FOR CANCER 
THERAPEUTICS  !
The platform in this thesis was developed with two main goals in mind: (1) to 
encapsulate a therapeutic cargo as the platform circulated throughout the body, and (2) to 
trigger release of this cargo at a specific time and location. 
The first goal was accomplished by the utilization of a thermally-responsive 
poly(NIPAAm-co-AAm) hydrogel. This material acts similarly to a sponge, allowing 
therapeutic molecules to be absorbed within its pores. In addition, this hydrogel was found to 
have an LCST of 39-45 oC, thereby existing in a swollen state at physiologic temperature. 
The second goal was accomplished by the encapsulation of gold-silica nanoshells into 
the hydrogel. The nanoshells used in this thesis were tuned to have a peak absorption in the 
near-infrared range, where biological tissue is most permissive to light. When exposed to 
light in this range, the nanoshells heated and elicited a temperature increase of surrounding 
material. This caused the hydrogel material to collapse and rapidly expel large amounts of 
water, demonstrating the capability of optically triggering this material phase transition. 
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Next, it was shown that this material could be loaded with various cancer therapeutics. 
Both a chemotherapeutic (doxorubicin) and a biologic therapy (dsDNA, as a model for 
siRNA) were passively absorbed into the material, and rapid release of both therapies 
followed exposure to NIR irradiation. Furthermore, the heating necessary to trigger this 
release did not appear to detrimentally effect dsDNA integrity. 
Further work was done to synthesize this composite material in the form of nanoscale 
particles through the use of a dissolvable gelatin template. TEM images indicated that the 
resulting particles consist of a nanoshell core surrounded by a hydrogel. The hydrodynamic 
diameter of these particles decreased in response to either incubation at 50 oC or exposure to 
NIR irradiation, proving that these particles retained the same thermal properties as the bulk 
material. This material has the potential to act as a minimally invasive delivery platform, as 
the nanoscale particles could be loaded with a therapeutic and injected intravenously. The 
platform would leak out of tumor vasculature and passively accumulate at the site of 
malignant tissue, at which time an external NIR laser would be used to elicit a temperature 
increase and release of the therapeutic payload.    
6.2 FUTURE DIRECTIONS !
The ability to control therapeutic delivery to malignant tissue would undoubtedly 
improve cancer management by overcoming limitations of current therapies. The controlled 
release system designed in this thesis would decrease the off-site toxicities of systemic 
chemotherapeutic regimens by minimizing drug exposure to non-malignant tissue, as well as 
increase the serum stability of fragile biologic therapeutics. The poly(NIPAAm-co-AAm)-
gold nanoshell platform can be loaded with cancer therapeutics, and their release can be 
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optically-triggered. In addition, this material can be synthesized as sub-micron particles, 
giving it the potential to act as a minimally-invasive, controlled therapeutic delivery platform. 
Future work looking at loading and release of therapeutics from the nanoscale particles, as 
well as in vitro and in vivo efficacy experiments would further advance this platform. 
Ultimately, this single platform could also attack tumor tissue using three distinct 
mechanisms simultaneously: (1) photothermal heating, (2) chemotherapeutic delivery, and 
(3) gene silencing due to siRNA, providing a novel approach to effectively treat cancers 
when standard treatment modalities are not adequate. 
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